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Cellular Biology
Wnt Signaling Exerts an Antiproliferative Effect on Adult
Cardiac Progenitor Cells Through IGFBP3
Angelos Oikonomopoulos, Konstantina-Ioanna Sereti, Frank Conyers, Michael Bauer, Annette Liao,
Jian Guan, Dylan Crapps, Jung-Kyu Han, Hanhua Dong, Ahmad F. Bayomy, Gabriel C. Fine,
Karen Westerman, Travis L. Biechele, Randall T. Moon, Thomas Force, Ronglih Liao
Rationale: Recent work in animal models and humans has demonstrated the presence of organ-specific
progenitor cells required for the regenerative capacity of the adult heart. In response to tissue injury,
progenitor cells differentiate into specialized cells, while their numbers are maintained through mechanisms
of self-renewal. The molecular cues that dictate the self-renewal of adult progenitor cells in the heart,
however, remain unclear.
Objective: We investigate the role of canonical Wnt signaling on adult cardiac side population (CSP) cells under
physiological and disease conditions.
Methods and Results: CSP cells isolated from C57BL/6J mice were used to study the effects of canonical Wnt
signaling on their proliferative capacity. The proliferative capacity of CSP cells was also tested after injection of
recombinant Wnt3a protein (r-Wnt3a) in the left ventricular free wall. Wnt signaling was found to decrease the
proliferation of adult CSP cells, both in vitro and in vivo, through suppression of cell cycle progression. Wnt
stimulation exerted its antiproliferative effects through a previously unappreciated activation of insulin-like
growth factor binding protein 3 (IGFBP3), which requires intact IGF binding site for its action. Moreover,
injection of r-Wnt3a after myocardial infarction in mice showed that Wnt signaling limits CSP cell renewal,
blocks endogenous cardiac regeneration and impairs cardiac performance, highlighting the importance of
progenitor cells in maintaining tissue function after injury.
Conclusions: Our study identifies canonical Wnt signaling and the novel downstream mediator, IGFBP3, as
key regulators of adult cardiac progenitor self-renewal in physiological and pathological states. (Circ Res.
2011;109:1363-1374.)
Key Words: cardiac side population cells  Wnt signaling  cardiac regeneration  stem cells  proliferation
Accumulating evidence over the past decade in bothhumans and animal models has documented the pres-
ence of endogenous progenitor cells in adult myocardium.1–6
In response to local tissue injury, cardiac progenitor cells
differentiate into specialized cells, while the pool of progen-
itor cells is maintained, in part, through self-renewal and
enhanced proliferation.7,8 However, the molecular cues and
signaling pathways that dictate the homeostasis of adult
progenitor cells and in particular their self-renewal, in phys-
iological and pathological states, remain unclear.
Wnt ligands constitute a family of 19 secreted glycopro-
teins that act as key regulators of cellular function during
development, adulthood, and disease.9,10 Several reports have
proposed time and context dependent roles for Wnt signaling
in cardiogenesis and progenitor cell biology.11 Studies in
chick and Xenopus embryos have demonstrated that inhibi-
tion of Wnt signaling is required for cardiac differentia-
tion,12,13 whereas Wnt signaling has also been found to
promote cardiomyogenesis in Drosophila and embryonic
carcinoma P19 cells.14,15 Moreover, early in gastrulation, Wnt
ligands activate a cardiac differentiation program, whereas at
later stages they act as potent inhibitors of the cardiomyo-
genic differentiation.16,17 Recent genetic studies have demon-
strated that the canonical Wnt signaling cascade promotes the
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proliferation of neonatal and embryonic Isl-1 cardiac pro-
genitors in vitro and in vivo.18–20 Little is known, however,
regarding the role of Wnt signals in modulating adult pro-
genitor cell populations.
Side population (SP) cells were initially identified based on
their unique ability to efflux the DNA binding dye Hoechst
33342,21 and were found to retain the long-term regenerative
potential of bone marrow. Subsequently, SP cells were
identified in various adult tissues/organs including adult
myocardium.22 Cardiac SP (CSP) cells are enriched in Sca1
but do not express c-kit or Isl-1.6 More importantly, CSP cells
are found to be capable of differentiation into functional
cardiac myocytes in vitro or in vivo after myocardial infarc-
tion (MI).6,23–25 We demonstrate that in contrast to previous
work in embryonic or early postnatal stem cells, Wnt signal-
ing negatively regulates the proliferation of adult CSP pro-
genitor cells, both in vitro and in vivo, through suppression of
cell cycle progression. Moreover, Wnt activation exerts its
antiproliferative effects through a previously unappreciated
activation of IGFBP3, which is found to require intact IGF
binding site for its action. Importantly, activation of Wnt
signaling was found to limit CSP cell renewal after MI,
impair endogenous regenerative capacity, and worsen
post-MI structural and functional remodeling. Overall, our
study represents the first investigation of the role of canonical
Wnt pathway in the homeostasis of adult cardiac progenitor
cells in both physiological and pathological states and high-
lights the importance of cardiac progenitor cells in maintain-
ing tissue function after injury.
Methods
An expanded Methods section describing all procedures and
protocols is available in the Online Data Supplement at
http://circres.ahajournals.org.
Animals
C57BL/6J male and female mice (8–12 weeks old) were purchased
from Jackson Laboratory (Jackson East, MP 15). All animal proce-
dures and handling were performed under the guidelines of Harvard
Medical School, the Longwood Medical Area Institutional Animal
Care and Use Committee (IACUC), and the National Society for
Medical Research. MI was generated in C57BL/6J female mice as
previously described.26 MI size was estimated using histological
imaging of three transverse myocardial sections (base, midpapillary,
and apex) after staining with Masson trichrome, as previously
described.27
Intramyocardial Injection of Recombinant Wnt3a
or Recombinant IGFBP3
Ten microliters of recombinant Wnt3a (r-Wnt3a, 400 ng) or recom-
binant IGFBP3 (r-IGFBP3) proteins (1000 ng) (R&D) or vehicle
(PBS) was given by intramyocardial injection into 3 sites of the left
ventricular free wall of nonsurgically operated female mice
(r-Wnt3a) or into the infarct/border zone area of mice immediately
after MI (r-Wnt3a or r-IGFBP3).
Heart Fixation and Histology
One day after echocardiographic measurements, animals were eu-
thanized and hearts were fixed at an end-diastolic pressure of
5 mm Hg, using a Langendorff apparatus. For details, see Methods in
the Online Data Supplement.
Echocardiography
Echocardiography was performed 1 day before MI and 7 days after
MI using a high-resolution, high-frequency digital imaging system
(Vevo 2100, VisualSonics), as previously described.28 For details,
see Methods in the Online Data Supplement.
FACS Analysis
FACS was performed using a FACSAria (Becton Dickinson, BD)
equipped with 3 lasers (488 nm, 633 nm, 355 nm). Hoechst 33342
dye was excited by an UV (355 nm) laser. Acquired data were
analyzed by FACSDIVA software (BD Biosciences).
RNA Isolation and RT-PCR
RNA was extracted from CSP cells using Trizol reagent (Invitrogen)
followed by RNeasy Mini Kit (Qiagen). Genomic DNA was re-
moved using Turbo-DNA free kit (Ambion). cDNA was generated
using a reverse transcription synthesis kit (Bio-Rad) and RT-PCR
was performed in a MyiQ cycler (Bio-Rad). Primer sequences are
available on request.
Luciferase Assays
Luciferase activity was measured using a dual luciferase kit (Pro-
mega). Cell lysates were prepared from trypsinized CSP cells and
used to determine the values of Firefly and Renilla luciferases, with
a 20/20n Luminometer (Turner Biosystems).
Statistical Analysis
Statistical differences were evaluated using 1-way ANOVA analysis
and Student unpaired t test, using GraphPad Prism (Version 5.03).
Data are presented as meanSEM. A probability value 0.05 was
considered statistically significant.
Results
Wnt3a Negatively Regulates the Growth Potential
of CSP Cells Both In Vitro and In Vivo
Given the context dependency of Wnt signaling, we
examined the role of Wnt signals in mediating the prolif-
erative capacity of adult CSP cells. Under unstimulated
conditions, application of recombinant SFRP2 (Soluble
Frizzled-related Protein 2), a known Wnt antagonist,29 did
not affect the proliferation capacity of CSP cells in vitro,
suggesting that Wnt activity in baseline CSP cells in vitro
is relatively low (Online Figure I). Treatment of CSP cells
with increasing doses of Wnt3a-conditioned medium
(Wnt3a-CM) resulted in a gradual activation of the canon-
ical Wnt signaling pathway, as assessed by a T-cell
factor-controlled luciferase reporter assay30 and a respec-
tive decrease in CSP cell number, in comparison to
vehicle-conditioned medium treated cells (Figure 1A and
1B). A similar decrease in cell proliferation in response to
activation of canonical Wnt signaling was also observed in
CSP cells treated with recombinant Wnt3a protein (r-
Wnt3a) (Figure 1C and 1D). Likewise, BIO ((2Z, 3E)-6-
Non-standard Abbreviations and Acronyms
CSP cardiac side population
IGF insulin growth factor
IGFBP3 insulin growth factor binding protein 3
MI myocardial infarction
SP side population
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Bromoindirubin-3-oxime), a GSK-3 inhibitor, caused a
comparable decline in CSP cell number with correspond-
ing activation of the Wnt pathway (Figure 1E and 1F). We
further examined the antiproliferative effects of Wnt sig-
naling on CSP cells in vivo, with direct intramyocardial
injection of r-Wnt3a protein into the LV free wall of
normal adult mouse hearts. Injection of r-Wnt3a substan-
tially reduced the number of CSP cells (Figure 1G) in the
injected area relative to vehicle, whereas the number of
CSP cells remote to the injection site (atria, septum and
right ventricle) remained unchanged (Figure 1H).
Wnt3a Directly Alters the Cell Cycle Progression
of Adult CSP Cells
To further investigate the antiproliferative effect of canonical
Wnt signaling on CSP cells, we examined the effect of Wnt3a
on cell cycle progression in CSP cells. Treatment of CSP cells
with Wnt3a-CM led to a drastic reduction of cells residing in
the cell cycle S phase, as evidenced by decreased BrdU
incorporation (Figure 2A through 2C). Moreover, activation
of canonical Wnt signaling decreased the fraction of CSP
cells residing in the cell cycle M phase, as shown by
immunostaining for the phosphorylated form of histone H3
Figure 1. Canonical Wnt signaling
pathway mediates antigrowth effects
on CSP cells. Treatment of CSP cells
with increasing concentrations of A,
Wnt3a-CM (n3); C, r-Wnt3a (n3); and
E, BIO (n6) activated the canonical
Wnt signaling pathway, as measured by
the T-cell factor–luciferase reporter
assay. Corresponding proliferation
assays using the same dosages of B,
Wnt3a-CM (n4); D, r-Wnt3a (n4); and
F, BIO (n6) revealed decreased growth
capacity of CSP cells. T-cell factor–lu-
ciferase activity is measured in relative
light units (RLU). Analysis of CSP cell
number in G, the vehicle- or r-Wnt3a-
injected areas (left ventricular free wall)
(vehicle, n14; r-Wnt3a, n16), and in
H, the remote areas from the injection
sites (atria, septum, right ventricle) (vehi-
cle, n12; r-Wnt3a, n13). Data are
meanSEM. *P0.05 all samples to
respective vehicle, #P0.05, Wnt 10%
to Wnt 30%; BIO, 1 mol/L to BIO
2 mol/L and BIO 5 mol/L; §P0.05,
BIO 2 mol/L to BIO 5 mol/L. Cell
number in fold change presented in B,
D, and F is normalized to respective
vehicle group.
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(p-H3) (Figure 2D through 2F). The altered cell cycle profile
in Wnt3a-CM–treated CSP cells was further tested by direct
measurement of DNA content with propidium iodide stain-
ing. As demonstrated in Figure 2G through 2I, Wnt3a-CM
treatment considerably increased the amount of cells residing
in G0/G1-cell cycle phases while decreasing the fraction of
cells residing in S- and G2/M-cell cycle phases, in compari-
son to vehicle treated CSP cells.
To further clarify the role of Wnt signaling in the regula-
tion of CSP cell cycle progression, we examined the expres-
sion pattern of known cell cycle regulator genes. Consistent
with the impaired proliferative capacity, treatment of CSP
cells with Wnt3a-CM, in comparison to vehicle, downregu-
lated the expression of several positive cell-cycle regulators
including Ki67, PCNA, and Brca2, while upregulating neg-
ative cell-cycle regulators such as Gadd45a and p16
(Cdkn2a), within 8 hours (Online Table I). Notably, this gene
expression pattern persisted throughout later time points and
was accompanied by further downregulation of additional
cell cycle regulators, including c-myb, Ccnf, Ccnb1, Cdk4,
Mcm3, Mcm2, Cdc25a, Brca1, and Wee1 (Online Table I).
These findings suggest that canonical Wnt stimulation im-
pairs the proliferation of adult cardiac progenitor cells poten-
tially through modulation of cell-cycle regulators.
IGFBP3 Is Upregulated in Response to Activated
Wnt Signaling in CSP Cells
Using an RT-PCR-based array to monitor several key intra-
cellular signaling pathways, we sought to identify possible
mediators for the antiproliferative action of Wnt signaling.
Several genes previously identified to be associated with Wnt
signaling activation (Wnt2, Tcf7, Lef1) and with cell-cycle
regulation (p16) were found to be significantly upregulated in
Wnt3a-CM–treated CSP cells in comparison to vehicle-
treated cells (Online Figure II, A, and Online Table II).
Interestingly, among those genes examined, IGFBP3 exhib-
ited the most robust upregulation with Wnt activation, in-
creasing more than 40-fold (Online Figure II, A). Further-
more, IGFBP3 gene expression was upregulated by
Wnt3a-CM in CSP cells in a time-dependent manner (Figure
Figure 2. Activation of the canonical Wnt signaling pathway in CSP cells blocks cell cycle progression. Immunocytochemical
analysis of A, BrdU incorporation (n5), and D, expression of p-H3 (n4) in CSP cells, after treatment with Wnt3a-conditioned medium
(Wnt3a-CM) or vehicle. Representative images of (B and C) BrdU and (E and F) p-H3 CSP cells, in low (scale bars, 50 m) and high
magnification (inset, scale bars, 5 m). G, Flow cytometric analysis of CSP cells stained with propidium iodide (PI) (n4). Representa-
tive examples of PI analysis after treatment with vehicle (H) or Wnt3a-CM (I). Data are meanSEM. *P0.05.
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3A). Consistent to the increased gene expression, IGFBP3
protein levels were found increased in CSP cells treated with
Wnt3a-CM (Online Figure II, B). To examine whether
increased IGFBP3 was derived from de novo transcription,
stabilization of IGFBP3 mRNA, or by alternative mecha-
nisms, CSP cells were treated with actinomyosin-D, an
inhibitor of de novo transcription. Actinomyosin-D abolished
Wnt-mediated upregulation of IGFBP3, suggesting that the
IGFBP3 induction after Wnt3a treatment was mediated pre-
dominantly by transcriptional mechanisms (Figure 3B).
These experiments identify IGFBP3 as a potential mediator
of Wnt3a signaling in adult cardiac progenitor cells.
IGFBP3 Is Sufficient to Inhibit the Proliferative
Capacity of CSP Cells
To test whether the expression of IGFBP3 was sufficient to
mimic the antiproliferative effects of Wnt3a, we constructed
a lentiviral-vector overexpressing IGFBP3 (IGFBP3 o/e) in
CSP cells (Online Figure III). We found that the proliferative
capacity of CSP cells overexpressing IGFBP3 was markedly
decreased (Figure 3C). Consistent with this observation,
overexpression of IGFBP3 resulted in a cell cycle gene
expression pattern similar to that of canonical Wnt signaling,
with approximately 80% of examined genes (66 genes of a
total of 84 genes tested) similarly regulated in both experi-
Figure 3. IGFBP3 mediates antiprolif-
erative effects of the Wnt signaling
pathway on CSP cells. A, Time course
gene expression analysis of IGFBP3 in
CSP cells after treatment with vehicle or
Wnt3a-CM (n3). B, IGFBP3 gene
expression analysis in CSP cells after
pretreatment with Actinomyosin-D (30
minutes) and subsequent application of
vehicle or Wnt3a-CM (24 hours) (n3).
C, Proliferation assay of mock and
IGFBP3 (IGFBP3 o/e)-infected CSP cells
(n5). Proliferation assay of sh-Scramble
(D) and sh-IGFBP3-infected (E) CSP
cells (n4) after treatment with vehicle
or Wnt3a-CM. Scatterplot analysis of the
Ct values of cell cycle–related genes, in
sh-Scramble (F) and sh-IGFBP3-infected
(G) CSP cells, after treatment with vehi-
cle or Wnt3a-CM for 5 days. Outer diag-
onal lines indicate 2-fold changes.
Black, blue, and red circles represent
unchanged, upregulated, and downregu-
lated genes after Wnt activation, respec-
tively. H, Proliferation assay of mock,
IGFBP3 o/e, and IGFBP3mIGF-infected
CSP cells (n3). Data are meanSEM.
*P0.05 to respective vehicle or mock,
#P0.05 IGFBP3mIGF to IGFBP3 o/e.
Cell number in fold change presented in
B, C, D, and G was normalized to
respective vehicle or mock.
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mental conditions (Online Table III). Overall, our data
suggest that IGFBP3 acts as a mediator of Wnt signaling that
is sufficient to recapitulate the phenotypic response to Wnt
activation in CSP cells.
IGFBP3 Is Required for Wnt3a-Mediated
Antiproliferative Effects in CSP Cells
To determine whether IGFBP3 is required for the antiprolif-
erative effects of Wnt3a, we decreased IGFBP3 protein
expression in CSP cells by using lentiviral-mediated expres-
sion of a shRNA targeting IGFBP3 (sh-IGFBP3) (Online
Figure IV) before Wnt activation. Scramble-infected (sh-
Scramble) CSP cells treated with Wnt3a-CM exhibited de-
creased proliferation (Figure 3D), similar to uninfected cells.
In contrast, silencing of IGFBP3 prevented Wnt-mediated
inhibition of CSP cell proliferation (Figure 3E). To further
investigate the role of IGFBP3 in mediating the antiprolifera-
tive effects of Wnt signaling at the gene level, we compared
the expression profile of cell cycle-related genes in sh-
Scramble and sh-IGFBP3 CSP cells after treatment with
vehicle or Wnt3a-CM. In sh-Scramble CSP cells, 40 of the 75
(53%) expressed cell-cycle related genes were altered (up-
regulated or downregulated) by more than 2-fold after treat-
ment with Wnt3a-CM (Figure 3F and Online Table IV),
including upregulation of cell-cycle inhibitors (Cdkn2a and
Cdkn1a) and downregulation of positive mediators of cell-
cycle progression (Ccna2, Ccnb1, E2f3, Ki67, PCNA, Mcm2,
Mcm3, Mcm4, and Wee1). In sh-IGFBP3 CSP cells, only 12
of the 75 examined cell cycle regulators (16%) were altered
by more than 2-fold after treatment with Wnt3a-CM (Figure
3G and Online Table IV). In sh-IGFBP3–infected CSP cells,
Wnt signaling did not result in altered expression of negative
cell-cycle regulators and even upregulated the expression of
several positive regulators (Ccna2, Ccnb1, Wee1). Overall,
our data suggest that silencing of IGFBP3 results in normal-
ization of cell cycle gene expression in response to Wnt
signaling activation and that IGFBP3 is necessary for the
antiproliferative effects of Wnt3a activation in adult CSP
cells.
Integrity of IGF-Binding Site Is Required for the
Antiproliferative Effect of IGFBP3 on CSP Cells
IGFBP3 is an abundant circulating IGF-binding protein and
acts as a modulator of cell survival, cell proliferation, and cell
metabolism through IGF-dependent or IGF-independent
mechanisms.31 IGFBP3 is known to bind IGFs both in vitro
and in vivo.31 IGF-1 is a potent stimulant of several cell types
including adult cardiac stem cells.32 We found that IGF-1
stimulates CSP cell proliferation in vitro (Online Figure V,
A). However, the expression of IGF-1 receptors did not
change after Wnt3a treatment (Online Figure V, B and C). To
determine whether IGF binding to IGFBP3 is required for the
antiproliferative effect of IGFBP3, we overexpressed wild-
type IGFBP3 or mutated IGFBP3 with loss of the IGF
binding site (IGFBP3mIGF) in CSP cells.33 Overexpression of
wild-type IGFBP3 decreased cell proliferation, whereas over-
expression of IGFBP3mIGF increased cell division (Figure
3H), suggesting that the IGF binding site is critical for the
antiproliferative function of IGFBP3 in CSP cells.
Administration of r-Wnt3a Protein After MI
Diminishes the Pool of Endogenous
Cardiac Progenitors
After cardiac injury, CSP cell pools are acutely depleted and
later renewed, in part, through enhanced proliferation of local
CSP cells.26 Given the context and cell-type dependency of
Wnt activation in response to cardiac injury, we measured
Wnt-related genes in CSP cells isolated from the myocardium
1, 3, and 7 days after coronary ligation. Using a Wnt pathway
focused gene array, we established that Wnt-related genes
were downregulated in CSP cells early after MI and contin-
ued to decline over 7 days. Conversely, a corresponding
increase in Wnt pathway inhibitor genes was detected (Figure
4A through 4C and Online Tables V through VIII). During
this early post-MI period, CSP proliferation increased, as
shown by BrdU labeling (Figure 4D). To determine whether
activation of Wnt signaling may inhibit the growth capacity
of CSP cells after tissue injury, r-Wnt3a was injected into the
infarct and border zone of mouse hearts after MI. Injection of
r-Wnt3a after MI upregulated Wnt target genes, including
Ccnd1, Tcf7, Lef-1, and Wnt3a (Figure 5A), confirming the
activation of canonical Wnt in vivo. Administration of
r-Wnt3a resulted in a significant reduction in CSP cell
number in the region of injection (Figure 5B) but did not alter
CSP cell number in areas remote to the injection site (atria,
right ventricle and septum) relative to vehicle treated animals
(Figure 5C). To further determine whether the Wnt-mediated
decrease in CSP pools alters myocardial regeneration after
MI, we determined the formation of new cardiomyocytes by
pulsing BrdU, a thymidine analog, through Alzet mini-
osmotic pumps for a period of 1 week. BrdU-positive
cardiomyocytes were found to reside primarily in the infarct
and border zone areas of the injured myocardium (Figure 6A)
and were significantly decreased after r-Wnt3a administration
compared with vehicle injected counterparts (Figure 6B),
suggesting an impairment in new cardiomyocyte generation.
Notably, the majority of BrdU-positive cardiomyocytes were
smaller in size in both r-Wnt3a and vehicle-injected hearts as
compared with nondividing, BrdU-negative cardiomyocytes
(Figure 6C). A representative cluster of BrdU-positive car-
diomyocytes located in the infarct/border zone area is pre-
sented in Online Figure VI. Our data show that activation of
Wnt signaling pathway diminishes the endogenous repair
mechanisms of the heart after MI.
Administration of Wnt or IGFBP3 Adversely
Affects Post-MI Cardiac Remodeling
We further determined whether diminished CSP pools and
myocardial regeneration after MI influence the development
of adverse cardiac remodeling. One week after MI, heart
weight/body weight (Figure 7A) and infarct size (Figure 7B)
were significantly increased with r-Wnt3a injection. More-
over, injection of r-Wnt3a protein and impaired myocardial
regeneration were associated with decreased intraventricular
septal wall thickness, increased left ventricular chamber
dimension, and impaired cardiac performance, marked by
reduced ratio of fractional shortening and fractional area
change, compared with vehicle-injected mice (Figure 7C
through 7F). Taken together, our data suggest that activation
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of Wnt signaling worsens the post-MI structural and func-
tional remodeling. Similarly, administration of r-IGFBP3 into
the infarct/border zone area acutely after coronary artery
occlusion resulted in a decrease in intraventricular septal
thickness and an increase in left ventricular chamber dimen-
sion, as well as a corresponding reduction in LV fractional
shortening and fractional area change (Figure 8A through
8D). Collectively, these data suggest that IGFBP3 mimics the
Figure 4. Wnt signaling pathway
expression profile in CSP cells after
MI. Three-dimensional diagrams show
expression profile of Wnt signaling-
related genes in CSP cells at 1 day after
MI (A), 3 days after MI (B), and 7 days
after MI (C) (n3). The gene correspond-
ing to each bar can be found in Online
Table VIII. The position (well) A1 in (A
through C) is located in the bottom right
corner of each diagram. D, Analysis of
CSP cell proliferation (BrdU incorpora-
tion assay) at 4 days after MI (n3).
Data are meanSEM. *P0.05.
Figure 5. Administration of r-Wnt3a
protein decreases the amount of CSP
cells after MI. A, Gene expression anal-
ysis of Wnt target genes (Cyclin-D1,
Tcf7, Lef1, and Wnt3a) in the infarct/bor-
der zone area (injection site) after
intramyocardial injection of r-Wnt3a pro-
tein (n3). Analysis of CSP cell number
3 days after MI, in B, the infarct/border
zone area (injection site), and C, the
remote areas (atria, septum, right ventri-
cle) of vehicle-injected or r-Wnt3a–in-
jected hearts (vehicle, n10, and
r-Wnt3a, n9). Data are meanSEM.
*P0.05.
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effects of r-Wnt3a on cardiac function in the presence of
ischemic myocardial injury.
Discussion
Detailed knowledge of the molecular cues that regulate
progenitor cell fate decisions in physiological and patholog-
ical states is of the utmost importance for achieving the
overarching goal of therapeutic cardiac regeneration. Wnt
signaling is a pivotal factor in the regulation of organogenesis
from embryonic development to aging, as well as in various
disease conditions.9,10 Although Wnt signaling is undoubt-
edly established to be critical for cardiogenesis during cardiac
development,11 its role in adult cardiac progenitor cells and
post-MI remodeling remains poorly understood. In this study,
we define the role of canonical Wnt signaling in regulating
the function of adult cardiac progenitor cells in vitro and in
vivo. Furthermore, we identify a previously unknown link
between canonical Wnt signaling and IGFBP3 and demon-
strate an important role for IGFBP3 in mediating Wnt
signaling effects in adult cardiac progenitor cells. Last, our
study emphasizes the functional significance of adult cardiac
progenitor cells in tissue regeneration after cardiac injury
such as MI.
The antiproliferative effects of Wnt signaling on CSP cells
appear to be mediated through its negative effects on the cell
cycle progression. Activation of Wnt signaling leads to
accumulation of CSP cells in the early nonproliferating
G0/G1 cell-cycle phases, while altering substantially the
expression profile of various cell cycle regulators. In contrast,
prior reports suggest that Wnt signaling potentiates the
expansion of embryonic and neonatal Isl-1 cardiac progen-
itor cells.18–20 The distinct response of CSP cells to Wnt
Figure 6. Injection of r-Wnt3a after MI
inhibits the formation of new cardio-
myocytes (CM). A, Representative fluo-
rescent microscope images of BrdU
CM located in the infarct/border zone
area 1 week after MI, presented in low
(10), medium (40), and high (63)
magnification power. White arrow-
heads, shown in 63 magnification,
indicate BrdU CM. B, Quantification of
BrdU incorporation in CM at 1 week
after MI in sham (n3), vehicle-injected
(n5), and r-Wnt3a–injected (n4)
hearts. C, Cell size distribution frequency
of BrdU CM in the infarct/border zone
area of vehicle (n3) and r-Wnt3a–in-
jected (n4) animals. Data are
meanSEM. *P0.05, all samples to
sham; #P0.05, r-Wnt3a to vehicle.
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signals in adult versus embryonic progenitor cells probably is
due to intrinsic differences of each cell type and to the highly
time and context dependent nature of Wnt signaling.11,17 The
milieu-dependent role of Wnt signaling is also supported by
recent evidence in the cancer biology field. Although Wnt
signaling is associated with oncogenic transformation, it has
recently been suggested that activation of Wnt signaling may
decrease proliferation in melanoma cancerous cells.34
Further, we demonstrated that IGFBP3 is transcriptionally
upregulated by Wnt signaling and that it is the critical
determinant of the antiproliferative effects of Wnt on CSP
cells. Importantly, this phenomenon depends on a functional
IGF binding site in IGFBP3. Analysis of the IGFBP3 gene
promoter sequence has revealed a number of conserved
transcriptional factor binding sites for factors such as
REPIN1, MYOD1, and NFATC.35–37 ChIP-chip and ChIP-seq
experiments have recognized a number of other transcrip-
tional factors that may bind to the promoter region of
IGFBP3.38 Recent reports suggest IGFBP5 is a potential
target of Wnt-mediated transcriptional activity.39,40 Among
the members of the IGFBP family, IGFBP3 has a high
structural and functional resemblance to IGFBP5,41,42 raising
the possibility that IGFBP3 is upregulated in CSP cells through
a direct Wnt-mediated transcriptional mechanism.
The role of IGFBP proteins in the adult myocardium is
largely unknown. The insulin-like growth factor axis (ratio of
IGF-1 to IGFBP3) has been introduced as a predictor of
clinical outcomes in heart failure patients.43 Moreover, mice
overexpressing IGFBP3 exhibited cardiac organomegaly.44
More recently, a direct link between cardiomyogenesis,
IGFBP proteins, and Wnt signaling was identified.45 IGFBP4
increases the cardiomyogenic differentiation of P19CL6 cells
and embryonic stem cells through inhibition of canonical
Wnt.45 However, IGFBP4 activates Wnt/-catenin transcrip-
Figure 7. Administration of r-Wnt3a
after MI leads to impaired cardiac
performance. A, Quantification of heart
weight–to–body weight ratios in sham
(n8), vehicle-injected (n12), and
r-Wnt3a–injected animals (n12). B,
Measurement of infarct size in vehicle
and r-Wnt3a–injected hearts (n8).
Echocardiographic assessment of C,
intraventricular septal thickness in dias-
tole (IVS;d); D, left ventricular internal
dimension in diastole (LVID;d); E, frac-
tional shortening; and F, fractional area
change (sham, n7; vehicle, n9;
r-Wnt3a, n10). All measurements were
performed at 1 week after MI. Data are
meanSEM. *P0.05, all samples to
sham; #P0.05, r-Wnt3a to vehicle.
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tional activity in a renal cancer cell line.46 Thus, a context-
dependent and cell type–dependent specificity may define the
interaction between IGFBP proteins and Wnt.
Activation of Wnt signaling decreases resident cardiac
progenitor cell renewal and negatively affects the myocardial
response to infarction. SFRP1 and SFRP2, 2 well-
documented Wnt signaling inhibitors, exert a potent cardio-
protective effect after ischemic myocardial injury.47–50 Simi-
larly, depletion of -catenin attenuates post-MI cardiac
remodeling and improves animal survival by stimulating the
resident cardiac stem cell pool.51 Wnt signaling has been
reported to be enhanced within the infarct-border zone, but
Wnt activation was limited to endothelial cells, smooth
muscle cells, CD31/Sca1 cells, c-kit/CD45 cells, and
fibroblasts.52,53 Results from the current study, however,
indicate that Wnt pathway genes were decreased in CSP cells
isolated from the infarcted heart, whereas Wnt inhibitors,
such as SFRP2, increased. Consistent with this observation,
we found that CSP cell proliferation was enhanced early after
MI. Conversely, activation of Wnt signaling in CSP cells
through the delivery of recombinant Wnt protein decreased
the number of CSP cells. On the basis of in vitro data, it is
reasonable to speculate that downregulation of Wnt signaling
in CSP cells may promote the proliferation of CSP cells after
cardiac injury. In addition to the effects on cardiac progenitor
cells, r-Wnt3a may influence other cell types, including
cardiomyocytes. Indeed, we found that r-Wnt3a leads to an
increase in cardiomyocyte death (Online Figure VII, A), but
no change is observed in cell death when all cardiac cells are
considered (Online Figure VII, B). Importantly, recombinant
Wnt3a results in an increase in heart weight–to–body weight
ratio, although cardiomyocyte cross-sectional area remains
unchanged. These results do not exclude an increase in
myocyte length, which may contribute to the expansion in
cavitary volume (Online Figure VIII). Although we cannot
exclude that Wnt affects other cell types, our findings point to
a potential interaction between impaired progenitor cell
function and negative outcome after MI. Importantly, future
research is necessary to determine those cell types which
underlie the in vivo effects of recombinant Wnt administra-
tion and whether targeting Wnt may be a viable therapeutic
option.
In summary, our work reveals a novel role of Wnt
signaling pathway in adult cardiac progenitor cells and shows
that canonical Wnt ligands compromise the self-renewal
properties of CSP cells in vitro and in vivo. This phenome-
non, in turn, may lead to impaired cardiac recovery after
ischemic injury. Furthermore, we have identified a previously
unrecognized link between Wnt signaling and IGFBP3,
which together regulate cardiac progenitor cell function.
Canonical Wnt contributes to negative left ventricular remod-
eling by interfering with the endogenous myocardial regen-
eration. Understanding the molecular signals that modulate
tissue homeostasis and repair is important for the design of
novel therapeutic strategies for the failing heart.
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Novelty and Significance
What Is Known?
● Cardiac side population (CSP) cells represent an endogenous pool of
progenitor cells in the adult heart.
● The molecular mechanisms that dictate the homeostasis and cell fate
of CSP cells remain elusive.
● Wnt signals are key molecules that govern cardiac development and
proliferation of embryonic stem cells, though their role in regu-
lating adult cardiac progenitor cells remains unknown.
What New Information Does This Article Contribute?
● Activation of Wnt signaling pathway negatively regulates the
proliferation capacity of adult CSP cells and compromises the
endogenous regenerative capacity of the heart after myocardial
infarction.
● Wnt stimulation exerts its antiproliferative effects through a previ-
ously unappreciated transcriptional activation of insulin-like
growth factor binding protein 3 (IGFBP3).
Designing novel therapeutic approaches to modulate the endog-
enous regenerative capacity of the failing heart represents a
desirable, although challenging, task. Understanding the basic
mechanisms that control homeostasis of cardiac precursors,
such as CSP cells, is of fundamental importance in achieving
this goal. The Wnt signaling pathway is a key modulator of
cardiac development and a major factor that determines cell
fate, particularly in embryonic stem cell populations. However,
the role of Wnt signaling in adult cardiac progenitor cells
remains unclear. Our work reveals an antiproliferative effect for
Wnt signaling in adult CSP cells through a previously unappre-
ciated transcriptional interaction with IGBFP3 and direct regu-
lation of CSP cell cycle progression. After cardiac injury in vivo,
Wnt signaling is downregulated in CSP cells with corresponding
increase in CSP cell proliferation. Increasing Wnt stimulation
after myocardial infarction in CSP cells compromises the
endogenous regenerative capacity of the heart and is associated
with worsening of cardiac remodeling. Our findings demonstrate
that canonical Wnt signaling is a potent modulator of endoge-
nous adult cardiac progenitor cells and suggest that modulation
of Wnt signaling or IGFBP3 may could be an effective therapeutic
strategy for promoting cardiac regeneration.
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 1 
 
SUPPLEMENTAL MATERIAL 
Detailed Methods 
 
Myocardial infarction: MI was generated via permanent coronary ligation as previously 
described.1  C57BL/6J male mice (8-10 weeks old) were anesthetized using 65 mg/kg 
pentobarbital.  Mice were ventilated using a standard rodent ventilator.  An incision was 
performed between the fourth and the fifth intercostals space.  After the pericardium was 
removed a descending coronary artery was permanently ligated with a silk suture.  Sham-
operated animals underwent an identical surgical operation lacking the occlusion of the 
coronary artery.  To prevent any post-operative discomfort animals received buprenorphine 
(0.03-0.06 mg/kg).  Immediately after myocardial infarction and injection of r-Wnt3a protein 
osmotic minipumps (Alzet, 1007D) were implanted subcutaneously in the back of each 
mouse.  Each pump was loaded with BrdU dissolved in NaHCO3 (150 mmol/L) buffer at a 
concentration of 40 mg/ml.  BrdU pumps remained in place for a period of 7 days.    
 
Heart fixation:  Mice were anesthetized by intra-peritoneal injection of pentobarbital (65 
mg/ml) followed by intra-peritoneal administration of 100 IU/ml anticoagulant heparin.  
Hearts were rapidly excised and washed briefly in Krebs buffer (NaCl 137 mmol/L, KCl 4.0 
mmol/L, CaCl2 1.8 mmol/L, KH2PO4 1.2 mmol/L, MgSO4 1.2 mmol/L, NaHCO3 24.9 mmol/L, 
and dextrose 11.2 mmol/L (pH 7.4)).  A short cannula was connected to the aortic root to 
initiate retrograde perfusion by the Langendorff apparatus.  A thin cannula was pierced 
through the apex of the left ventricle (LV) to vent the besian drainage.  A ventricular balloon 
was inserted into the LV through the mitral valve via an incision in the left atrium.  The 
balloon was connected to a pressure transducer (Statham P23Db, Gould) for recording the 
LV pressure.  Hearts were paced (Grass Instruments) with platinum wires placed on the 
epicardial surface of the right ventricle.  Coronary perfusion pressure was held constant 
during the duration of the experiment at 80 mm Hg.  The balloon was inflated with saline to 
adjust the end-diastolic pressure (EDP) to 5 mm Hg.  When the end-diastolic pressure 
reached 5 mm Hg, hearts were arrested in diastole with KCl and were perfused with 10% 
buffered formalin solution at a hydrostatic pressure of 40-50 mm Hg for 15 minutes.  Hearts 
remained overnight in 10% buffered formalin solution at 4oC. Subsequently, the balloon and 
the excess formalin were removed and the hearts were weighed.  Hearts were imbedded in 
paraffin, cut in three parts (apex, middle, base) and analyzed by immuno-histochemistry.   
 
Echocardiography:  Echocardiograms were obtained at baseline (1 day prior coronary 
occlusion) and 7 days following MI, with a Vevo 2100 Imaging digital ultrasound system 
(VisualSonics).  Echocardiography was performed using an 18-38 MHz linear-array 
transducer.  Prior to echocardiography the chest was shaved and the animals were placed 
on a heated platform in the supine position.  Echocardiographic analysis was performed in 
conscious mice at a physiological heart rate (>500 beats/minute).  Data acquisition was 
initiated with the parasternal cardiac long axis view and subsequently with a short axis view, 
at the level of mid-papillary muscles.  Echocardiographic measurements were performed 
from M-mode images.  All data were acquired and analyzed in a blinded fashion.  
 
Immuno-histochemistry.  Formalin fixed tissue slides were deparaffinized via incubation at 
65oC for 30 minutes and re-hydrated through sequential three minute incubations in xylene, 
ethanol (96%, 90%, 80%) and water.  Antigen retrieval was performed by microwave 
heating in citrate buffer (0.1 M, pH 6.0) for 10 minutes.  Slides were incubated with primary 
antibodies against BrdU (Roche) and α-sarcomeric-actin (Sigma) for 1 hour at 37oC, 
followed by incubation with appropriate secondary antibodies at the same conditions.  Slides 
were subsequently washed and mounted with DAPI-containing medium (Vector 
Vectashield).  Infarct area and border zone were scanned for the presence of BrdU positive 
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cardiomyocytes (CM) through examination of 10-20 mosaic-pictures of each section 
obtained by epi-fluorescence microscopy (Zeiss, Axiovert 200M).  Each mosaic picture was 
composed of 9-12 high power (63X) images.  The ratio of BrdU+ CM over total nucleated CM 
was calculated for every image.  Confocal imaging was performed with a LSM 700 system 
(Zeiss).  Image acquisition and analysis were performed in a blinded fashion.  Myocyte 
cross-sectional area was assessed by staining the cardiac tissue with Alexa Fluor 555 
conjugated wheat germ agglutinin (WGA) (Invitrogen).  Apoptotic cell death was determined 
by Tunel staining (Roche) according to the instructions of the manufacturer.  
 
RT-PCR gene array.  RNA samples from expanded CSP cells treated with Vehicle or 
Wnt3a-CM (a), CSP cells infected with Mock or IGFBP3-o/e (b), CSP cells infected with sh-
Scramble or sh-IGFBP3 (c) and freshly isolated CSP cells harvested from sham and post-MI 
(1, 3 and 7 days after injury) (d) were used for cDNA synthesis (RT2-First strand kit, 
SABiosciences).  RT-PCR gene-arrays (SABiosciences) focused on cell-cycle regulation (a, 
b and c),signal transduction pathways (b) and Wnt signaling pathway (d) were performed 
according to the instructions of the manufacturer using a MyiQ cycler (Bio-Rad).  Data were 
acquired from 3 independent experiments each with three replications and analysis was 
performed as follows:  ΔCt values of all examined genes were obtained by subtracting the 
mean threshold cycle (Ct) value of 5 housekeeping genes (Gusb, Hprt1, Hsp90ab1, Gapdh, 
Actb) from the Ct value of each gene.  Subsequently, ΔΔCt values for all genes were 
calculated as follows: ΔΔCt=ΔCt experimental –ΔCt control.  Fold differences were calculated 
based on the formula: Fold difference = 2-ΔΔCt.   
 
Production of Wnt3a conditioned medium (CM).  Vehicle-CM (Vehicle) and Wnt3a-CM 
were produced from L-M (TK-) cells and L-M (TK-)-Wnt3a cells according the instructions of 
American Type Culture Collection (ATCC). 
 
Cell expansion and lentiviral infection.  CSP cells were isolated as previously described2 
and cultured in expansion medium [α-MEM (Lonza) with 20% FBS (Hyclone), 2 mmoles/L, 
L-Glutamine and 1% penicillin/streptomycin] at a density of 10-15 cells/mm2.  CSP cells of 
passages 3-5 were infected with lentivirus and 48 hours later were used in proliferation 
assays.  Lentivirus with sh-Scramble, sh-IGFBP3, empty vector (Mock), IGFBP3-o/e, 
IGFBP3mIGF or pBARL (TCF-controlled luciferase reporter) and pSL9 (Ef1-a-controlled 
Renilla luciferase control)3, were used as described in the manuscript.  
 
Proliferative capacity assay.  In vitro proliferation capacity of CSP cells was determined by 
cell counting, cell cycle markers including BrdU and phospho-Histone H3 (p-H3), and DNA 
content measurements through propidium iodide (PI) staining.  Briefly, CSP cells were 
cultured at an initial density of 3.5-7 cells/mm2 in our established α-MEM based expansion 
medium with 20% FBS with various concentrations of Vehicle, Wnt3a-CM, BIO ((2′Z,3′E)-6-
Bromoindirubin-3′-oxime), IGF-1 (Peprotech), recombinant Wnt3a protein or recombinant 
SFRP2 (R&D).  Culture medium was replaced every 72 hours and following 6 days in 
culture, cell number was determined using hematocytometer and flow cytometer (C6 Accuri 
cytometer). For immuno-cytochemistry detection, CSP cells were cultured on coverslips in 
expansion medium for five days.  For BrdU incorporation assays, at day 5 CSP cells were 
pulsed with 10µM BrdU for 1 hour and BrdU was detected using a labeling kit (Roche) 
according to the instructions of the manufacturer.  p-H3 (Abcam) was detected by 
immunocytochemical staining as previously described.4  CSP cells were visualized using 
Zeiss epi-fluorescent microscopy.  For DNA content measurements, CSP cells were fixed 
using 70% ethanol following 5 days culture and were stained with PI (PBS, 0.1% Triton-X 
100, 2µg/ml PI, 400 ng/ml RNAse-A) for one hour at 37oC under light-free conditions.  CSP 
cells were analyzed by FACS and data were processed by ModFit Lt (Verity Software 
House). 
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IGFBP-3 over-expression:  IGFBP-3 cDNA was excised by XbaI/XmaI enzymatic digestion 
from vector pSport-6 (Open Biosystems).  The cDNA-fragment was blunted and ligated into 
lentiviral expression vector LSLV-83 (kindly provided by Dr. Paul Allen) downstream of the 
constitutively active promoter EF1a.  Infected cells were selected with neomycin (1mg/ml) 
for a period of 7-10 days. 
 
IGFBP-3 shRNA.  pLKO.1-puro lentiviral vectors encoding Scramble or IGFBP3 
(TRCN0000112128) shRNAs were obtained from Open Biosystems.  CSP cells were 
infected with lentiviruses and selected using puromycin treatment (4µg/ml) over a period of 
7-10 days.  
 
IGFBP-3 mutagenesis.  Lentiviral plasmid containing WT-IGFBP3 cDNA was utilized as a 
template for site-directed mutagenesis (quick-change mutagenesis kit, Stratagene), 
according to manufacturer’s instructions.  In brief, complementary primers encoding the 
desired mutations were annealed to the template LSLV-83-IGFBP3 plasmid and Pfu 
polymerase was used to replicate the template, incorporating the mutated primers.  The 
template plasmid was digested with DpnI, prior to transformation.  The utilized primers are 
as follows: 
IGFBP3mIGF-sense:CCCGCTGAGGGCGGGGGGGAATGGCCGCGGG 
IGFBP3mIGF-antisense:CCCGCGGCCATTCCCCCCCGCCCTCAGCGGG.  
All mutated plasmids were sequence verified.   
 
Cell viability assay:  Annexin-V staining (Abcam) was used to determine cell death, 
according to the instructions of the manufacturer, using a flow cytometer (C6 Accuri 
cytometer).  
 
Actinomyosin-D treatment:  CSP cells were treated with 5µg/ml Actinomyosin-D for a 
period of 30 minutes, prior to application of Vehicle or Wnt3a-CM (25%) for a period of 24 
hours.   
 
Western blot:  Immunoblot was performed as previously described.5  Primary antibodies 
against IGFBP3 (Santa Cruz) or GAPDH (R&D) followed by appropriate secondary 
antibodies (Alexa-Fluor 680, Molecular probes) were applied.  All incubations were 
performed for two hours at room temperature under constant movement.  Antibody binding 
was detected using the Odyssey infrared system (LI-COR).   
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Online Tables 
 
Online Table I:  Cell cycle-focused RT-PCR gene array in CSP cells treated with Vehicle or Wnt3a-CM. 
 
Cell cycle RT-PCR array 
Description Symbol 
8 hours  
(ΔCt) Fold 
change 
48 hours  
(ΔCt) Fold 
Change Vehicle Wnt3a-CM Vehicle 
Wnt3a-
CM 
Integrin beta 1 (fibronectin 
receptor beta) Itgb1 -1.87 -2.28 1.33 -0.14 -1.36 2.33* 
Cyclin-dependent kinase 
inhibitor 2A Cdkn2a 5.09 4.08 2.00* 2.52 1.49 2.04* 
Cyclin-dependent kinase 
inhibitor 1A (P21) Cdkn1a 0.17 0.34 -1.12 1.60 1.23 1.30 
Peripheral myelin protein 22 Pmp22 3.11 2.99 1.08 1.94 1.63 1.24 
Cyclin D1 Ccnd1 3.37 3.28 1.06 2.49 2.23 1.20 
Transformed mouse 3T3 cell 
double minute 2 Mdm2 2.61 2.64 -1.01 1.65 1.39 1.20 
DNA-damage inducible 
transcript 3 Ddit3 4.47 4.26 1.15 4.82 4.61 1.16 
Protein phosphatase 2 
(formerly 2A), regulatory 
subunit B'', alpha 
Ppp2r3a 9.88 9.90 -1.01 10.09 9.92 1.12 
Adenylate kinase 1 Ak1 1.85 1.67 1.13 2.82 2.68 1.10 
Protein phosphatase 1D 
magnesium-dependent, delta 
isoform 
Ppm1d 4.91 5.06 -1.10 4.24 4.74 -1.41* 
Structural maintenance of 
chromosomes 1A Smc1a 4.70 4.62 1.05 3.99 4.48 -1.41* 
Nucleophosmin/nucleoplasmin 
2 Npm2 9.83 9.90 -1.04 9.46 9.98 -1.43* 
Cell division cycle 25 homolog 
A (S. pombe) Cdc25a 3.36 3.55 -1.14 4.36 4.88 -1.44* 
Transcription factor Dp 1 Tfdp1 1.33 1.38 -1.03 1.04 1.60 -1.48* 
Stromal antigen 1 Stag1 5.04 5.51 -1.38 4.78 5.39 -1.52* 
Telomeric repeat binding factor 
1 Terf1 6.22 6.54 -1.24 4.71 5.34 -1.54* 
Cyclin B1 Ccnb1 4.54 4.46 1.05 3.17 3.80 -1.55* 
Proliferating cell nuclear 
antigen Pcna 1.71 2.03 -1.25* 0.92 1.57 -1.57* 
Protein phosphatase 3, 
catalytic subunit, alpha isoform Ppp3ca 4.67 5.07 -1.31 4.08 4.77 -1.62* 
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RAD21 homolog (S. pombe) Rad21 4.71 5.01 -1.22 1.95 2.65 -1.62* 
Cyclin-dependent kinase 4 Cdk4 2.13 2.47 -1.26 1.20 1.91 -1.63* 
Inhibin alpha Inha 8.30 8.48 -1.13 7.77 8.47 -1.63* 
Mdm2, transformed 3T3 cell 
double minute p53 binding 
protein 
Mtbp 8.32 8.67 -1.27 5.13 5.84 -1.63* 
Minichromosome maintenance 
deficient 3 (S. cerevisiae) Mcm3 2.95 3.10 -1.11 2.86 3.57 -1.64* 
MutS homolog 2 (E. coli) Msh2 4.23 4.23 -1.00 3.80 4.54 -1.66* 
Checkpoint kinase 1 homolog 
(S. pombe) Chek1 5.53 6.15 -1.53 5.48 6.22 -1.67* 
RAD9 homolog (S. pombe) Rad9 5.62 5.90 -1.21 5.19 5.97 -1.72* 
NIMA (never in mitosis gene 
a)-related expressed kinase 2 Nek2 N/A N/A N/A 4.28 5.07 -1.73* 
RAD51 homolog (S. 
cerevisiae) Rad51 6.23 6.86 -1.55 4.99 5.81 -1.77* 
MAD2 mitotic arrest deficient-
like 1 (yeast) Mad2l1 3.91 4.21 -1.2 3.28 4.12 -1.79* 
Transformation related protein 
53 Trp53 2.98 3.15 -1.12 1.83 2.68 -1.81* 
Retinoblastoma-like 1 (p107) Rbl1 5.51 5.96 -1.37 5.69 6.57 -1.85* 
Myeloblastosis oncogene Myb N/A N/A N/A 12.28 13.25 -1.96* 
Breast cancer 2 Brca2 6.72 8.67* -3.88* 6.67 7.70 -2.04* 
WEE 1 homolog 1 (S. pombe) Wee1 5.16 5.53 -1.29 5.24 6.27 -2.04* 
Breast cancer 1 Brca1 6.20 6.73 -1.44 5.58 6.62 -2.06* 
Cyclin F Ccnf 4.40 4.32 1.06 3.71 4.76 -2.06* 
Minichromosome maintenance 
deficient 2 mitotin (S. 
cerevisiae) 
Mcm2 4.23 4.47 -1.18 2.75 3.81 -2.07* 
Antigen identified by 
monoclonal antibody Ki67 Mki67 5.02 6.59 -2.96* 2.94 4.07 -2.19* 
Transformation related protein 
63 Trp63 10.02 9.90 1.08 10.58 13.40 -7.09* 
Calcium/calmodulin-dependent 
protein kinase II alpha Camk2a N/A N/A N/A 9.14 9.14 -1.00 
Polycystic kidney disease 1 
homolog Pkd1 4.06 3.80 1.20 3.74 3.76 -1.01 
Notch gene homolog 2 
(Drosophila) Notch2 6.57 6.80 -1.17 5.23 5.29 -1.04 
Microtubule-actin crosslinking 
factor 1 Macf1 2.53 2.61 -1.05 3.01 3.12 -1.07 
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Amyloid beta (A4) precursor 
protein-binding, family B, 
member 1 
Apbb1 9.45 8.78 1.59 8.76 8.87 -1.08 
Cyclin C Ccnc 6.36 6.59 -1.17 7.30 7.44 -1.10 
Tumor susceptibility gene 101 Tsg101 6.80 6.51 1.22 7.03 7.17 -1.10 
Nuclear factor of activated T-
cells, cytoplasmic, calcineurin-
dependent 1 
Nfatc1 2.99 3.02 -1.01 4.46 4.63 -1.12 
RAD17 homolog (S. pombe) Rad17 5.93 5.90 1.01 4.81 4.99 -1.13 
SMT3 suppressor of mif two 3 
homolog 1 (yeast) Sumo1 2.24 2.37 -1.09 2.10 2.28 -1.13 
TAF10 RNA polymerase II, 
TATA box binding protein 
(TBP)-associated factor 
Taf10 2.37 2.36 1.00 1.31 1.53 -1.16 
G protein-coupled receptor 132 Gpr132 N/A N/A N/A 12.38 12.60 -1.17 
Sestrin 2 Sesn2 7.65 7.39 1.19 5.57 5.80 -1.17 
RAN, member RAS oncogene 
family Ran -1.57 -1.44 -1.09 -1.58 -1.33 -1.19 
CDK5 regulatory subunit 
associated protein 1 Cdk5rap1 7.71 7.14 1.48 7.76 8.03 -1.2 
C-abl oncogene 1, receptor 
tyrosine kinase Abl1 N/A N/A N/A 9.49 9.76 -1.21 
E2F transcription factor 4 E2f4 2.73 2.93 -1.15 3.96 4.25 -1.22 
Pescadillo homolog 1, 
containing BRCT domain 
(zebrafish) 
Pes1 3.67 3.86 -1.13 2.20 2.50 -1.23 
DnaJ (Hsp40) homolog, 
subfamily C, member 2 Dnajc2 3.39 3.47 -1.05 3.22 3.54 -1.25 
Dystonin Dst 4.79 4.75 1.02 3.12 3.44 -1.25 
Protamine 1 Prm1 N/A N/A N/A 13.23 13.57 -1.26 
Retinoblastoma-like 2 Rbl2 6.52 6.78 -1.19 5.31 5.64 -1.26 
Growth arrest and DNA-
damage-inducible 45 alpha Gadd45a 6.55 5.96 1.50* 5.06 5.42 -1.28 
Cyclin-dependent kinase 2 Cdk2 4.61 5.06 -1.36 3.62 4.01 -1.31 
Caspase 3 Casp3 4.88 5.05 -1.12 4.79 5.20 -1.32 
E2F transcription factor 3 E2f3 6.44 6.56 -1.08 5.85 6.30 -1.36 
Src homology 2 domain-
containing transforming protein 
C1 
Shc1 2.93 2.88 1.03 3.85 4.30 -1.36 
Stratifin Sfn 7.34 6.98 1.28 8.39 8.85 -1.37 
Cyclin E1 Ccne1 6.99 6.98 1.00 5.01 5.47 -1.38 
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Proteasome (prosome, 
macropain) assembly 
chaperone 2 
Psmg2 4.83 5.23 -1.32 3.07 3.56 -1.4 
E2F transcription factor 1 E2f1 6.53 6.71 -1.12 5.48 5.98 -1.41 
CDC28 protein kinase 1b Cks1b 2.16 2.09 1.04 3.01 3.56 -1.46 
Cyclin-dependent kinase 
inhibitor 1B Cdkn1b 5.93 5.92 1.00 3.79 4.36 -1.48 
S-phase kinase-associated 
protein 2 (p45) Skp2 5.60 6.07 -1.37 5.42 6.00 -1.49 
Ataxia telangiectasia mutated 
homolog (human) Atm 5.42 6.23 -1.75 5.56 6.14 -1.50 
Meiotic recombination 11 
homolog A (S. cerevisiae) Mre11a 5.78 5.71 1.04 5.10 5.68 -1.50 
Hus1 homolog (S. pombe) Hus1 5.41 5.58 -1.11 6.29 6.94 -1.57 
Calcium/calmodulin-dependent 
protein kinase II, beta Camk2b 10.02 9.90 1.08 11.89 12.55 -1.58 
Cyclin A2 Ccna2 3.89 4.09 -1.15 3.55 4.25 -1.62 
Cyclin B2 Ccnb2 6.37 6.39 -1.01 4.10 4.91 -1.74 
Minichromosome maintenance 
deficient 4 homolog (S. 
cerevisiae) 
Mcm4 2.34 2.54 -1.14 2.32 3.18 -1.82 
E2F transcription factor 2 E2f2 N/A N/A N/A 11.09 12.32 -2.35 
Cyclin A1 Ccna1 N/A N/A N/A N/A N/A N/A 
Schlafen 1 Slfn1 N/A N/A N/A N/A N/A N/A 
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Online Table II:  Pathway finder focused RT-PCR gene array in CSP cells treated with Vehicle or 
Wnt3a-CM. 
 
Pathway finder RT-PCR array 
Description Gene # 
Gene 
Symbol 
ΔCt Fold 
change Vehicle Wnt3a-CM 
Insulin-like growth factor binding protein 3 31 Igfbp3 10.01 5.08 43.44* 
Wingless-related MMTV integration site 2 57 Wnt2 10.1 6.55 13.94* 
Fas (TNF receptor superfamily member 6) 20 Fas 8.08 5.15 10.14* 
Transcription factor 7, T-cell specific 49 Tcf7 8.47 5.55 9.81* 
Cyclin-dependent kinase inhibitor 2A (p16) 15 Cdkn2a 3.18 0.19 9.11* 
Lymphoid enhancer binding factor 1 37 Lef1 8.02 4.97 8.52* 
Prostate transmembrane protein, androgen 
induced 1 52 Tmepai 7.18 4.49 6.88* 
Etoposide induced 2.4 mRNA 19 Ei24 4.21 3.36 1.92* 
Heat shock protein 1 29 Hspb1 0.26 -0.63 1.92* 
Cyclin-dependent kinase inhibitor 2B (p15, 
inhibits CDK4) 16 Cdkn2b 5.94 2.46 12.33 
Intercellular adhesion molecule 1 30 Icam1 9.85 6.24 12.17 
Fatty acid synthase 21 Fasn 9.41 7.32 9.91 
FBJ osteosarcoma oncogene 23 Fos 9.12 7.07 9.83 
Bone morphogenetic protein 4 8 Bmp4 8.79 7.06 9.73 
Prostaglandin-endoperoxide synthase 2 46 Ptgs2 6.54 4.43 9.42 
Chemokine (C-C motif) ligand 2 10 Ccl2 6.9 6.87 8.74 
Baculoviral IAP repeat-containing 5 7 Birc5 6.33 7.85 8.61 
Myelocytomatosis oncogene 39 Myc 6.21 6.01 6.43 
Baculoviral IAP repeat-containing 2 5 Birc2 7.92 6.38 6.28 
B-cell leukemia/lymphoma 2 3 Bcl2 7.31 6.31 6.09 
WNT1 inducible signaling pathway protein 1 56 Wisp1 4.96 2.87 5.90 
Nuclear receptor interacting protein 1 42 Nrip1 7.93 6.37 4.71 
Transformed mouse 3T3 cell double minute 2 38 Mdm2 4.5 2.82 3.45 
Retinol binding protein 1, cellular 47 Rbp1 2.34 1.5 3.41 
Telomerase reverse transcriptase 50 Tert 8.16 6.66 3.34 
Cyclin-dependent kinase inhibitor 1A (P21) 13 Cdkn1a 0.88 -0.23 3.08 
Baculoviral IAP repeat-containing 3 6 Birc3 6.56 5.47 2.96 
Breast cancer 1 9 Brca1 6.82 7.74 2.85 
Patched homolog 1 45 Ptch1 6.35 4.98 2.84 
Homeo box A1 27 Hoxa1 7.48 6.32 2.77 
Jun oncogene 36 Jun 5.65 4.6 2.76 
TRAF family member-associated Nf-kappa B 
activator 48 Tank 5.97 5.66 2.75 
Peroxisome proliferator activated receptor 
gamma 44 Pparg 6.8 6.29 2.41 
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Inhibitor of kappaB kinase beta 33 Ikbkb 6.73 5.97 2.36 
Transferrin receptor 51 Tfrc 5.58 5.44 2.34 
Cyclin-dependent kinase 2 12 Cdk2 5.53 5.79 2.05 
Early growth response 1 18 Egr1 5.37 6.19 1.88 
Hexokinase 2 26 Hk2 4.76 4.2 1.55 
Bcl2-associated X protein 2 Bax 1.16 0.58 1.53 
Heat shock factor 1 28 Hsf1 4.37 3.84 1.52 
Ngfi-A binding protein 2 40 Nab2 5.53 5.36 1.49 
Vascular cell adhesion molecule 1 54 Vcam1 5.27 5.67 1.49 
Nuclear factor of kappa light polypeptide 
gene enhancer in B-cells inhibitor, alpha 41 Nfkbia 4.97 4.48 1.44 
Growth arrest and DNA-damage-inducible 45 
alpha 24 Gadd45a 4.69 4.36 1.43 
Insulin-like growth factor binding protein 4 32 Igfbp4 2.75 2.27 1.43 
Interferon regulatory factor 1 35 Irf1 5.86 5.4 1.43 
Cyclin-dependent kinase inhibitor 1B 14 Cdkn1b 6.77 7.02 1.33 
Bcl2-like 1 4 Bcl2l1 5.24 5.45 1.23 
Glycogen synthase 1, muscle 25 Gys1 4.86 4.65 1.20 
Vascular endothelial growth factor A 55 Vegfa 4.66 4.51 1.12 
Ornithine decarboxylase, structural 1 43 Odc1 2.11 2.14 1.05 
Activating transcription factor 2 1 Atf2 3.55 4.46 1.04 
Transformation related protein 53 53 Trp53 2.48 2.48 1.02 
Cyclin D1 11 Ccnd1 2.9 3.21 1.02 
Interleukin 4 receptor, alpha 34 Il4ra 6.09 6.67 0.73 
Fibronectin 1 22 Fn1 -1.26 -0.41 0.63 
CCAAT/enhancer binding protein (C/EBP), 
beta 17 Cebpb 1.68 2.55 0.60 
Bone morphogenetic protein 2 - Bmp2 N/A N/A N/A 
Chemokine (C-C motif) ligand 20 - Ccl20 N/A N/A N/A 
CD5 antigen - Cd5 N/A N/A N/A 
Cadherin 1 - Cdh1 N/A N/A N/A 
Colony stimulating factor 2 (granulocyte-
macrophage) - Csf2 N/A N/A N/A 
Chemokine (C-X-C motif) ligand 1 - Cxcl1 N/A N/A N/A 
Chemokine (C-X-C motif) ligand 9 - Cxcl9 N/A N/A N/A 
Cytochrome P450, family 19, subfamily a, 
polypeptide 1 - Cyp19a1 N/A N/A N/A 
Engrailed 1 - En1 N/A N/A N/A 
Fas ligand (TNF superfamily, member 6) - Fasl N/A N/A N/A 
Fibroblast growth factor 4 - Fgf4 N/A N/A N/A 
Forkhead box A2 - Foxa2 N/A N/A N/A 
Gene regulated by estrogen in breast cancer 
protein - Greb1 N/A N/A N/A 
Hedgehog-interacting protein - Hhip N/A N/A N/A 
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Interleukin 1 alpha - Il1a N/A N/A N/A 
Interleukin 2 - Il2 N/A N/A N/A 
Interleukin 2 receptor, alpha chain - Il2ra N/A N/A N/A 
Leptin - Lep N/A N/A N/A 
Lymphotoxin A - Lta N/A N/A N/A 
Matrix metallopeptidase 10 - Mmp10 N/A N/A N/A 
Matrix metallopeptidase 7 - Mmp7 N/A N/A N/A 
NLR family, apoptosis inhibitory protein 1 - Naip1 N/A N/A N/A 
Nitric oxide synthase 2, inducible - Nos2 N/A N/A N/A 
Selectin, endothelial cell - Sele N/A N/A N/A 
Selectin, platelet - Selp N/A N/A N/A 
Tumor necrosis factor - Tnf N/A N/A N/A 
Wingless-related MMTV integration site 1 - Wnt1 N/A N/A N/A 
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Online Table III:  Cell cycle-focused RT-PCR gene-arrays in CSP cells treated with Vehicle or 
Wnt3a-CM (48hours) and CSP cells infected with Mock or IGFBP3 o/e lentiviruses. 
 
Cell cycle RT-PCR array 
Symbol 
Wnt3a-CM treatment  
(48 hours) IGFBP3 o/e 
AVG ΔCt Fold change AVG ΔCt Fold change 
Vehicle Wnt3a-CM 
Wnt3a/ 
Vehicle Mock 
IGFBP3 
o/e 
IGFBP3-o/e / 
Mock 
Itgb1 -0.14 -1.36 2.33 -1.32 -1.63 1.24 
Cdkn2a 2.52 1.49 2.04 1.14 0.49 1.56 
Cdkn1a 1.6 1.23 1.3 0.57 -0.01 1.49 
Pmp22 1.94 1.63 1.24 0.83 0.39 1.35 
Ccnd1 2.49 2.23 1.20 0.95 0.7 1.19 
Mdm2 1.65 1.39 1.20 0.88 0.76 1.09 
Ddit3 4.82 4.61 1.16 2.9 2.75 1.11 
Ak1 2.82 2.68 1.10 1.21 0.79 1.33 
Notch2 5.23 5.29 -1.04 4.23 4.67 -1.36 
Macf1 3.01 3.12 -1.07 2.22 2.27 -1.04 
Rad17 4.81 4.99 -1.13 4.1 4.36 -1.2 
Taf10 1.31 1.53 -1.16 0.57 0.85 -1.22 
Sesn2 5.57 5.8 -1.17 4.25 4.27 -1.01 
Ran -1.58 -1.33 -1.19 -1.45 -1.06 -1.31 
Cdk5rap1 7.76 8.03 -1.20 6.79 6.84 -1.04 
E2f4 3.96 4.25 -1.22 3.14 3.41 -1.21 
Pes1 2.2 2.5 -1.23 2.01 2.29 -1.22 
Dnajc2 3.22 3.54 -1.25 2.74 3.09 -1.28 
Rbl2 5.31 5.64 -1.26 4.55 5.42 -1.83 
Cdk2 3.62 4.01 -1.31 3.83 4 -1.12 
E2f3 5.85 6.3 -1.36 5.3 5.33 -1.02 
Shc1 3.85 4.3 -1.36 2.63 2.76 -1.10 
Sfn 8.39 8.85 -1.37 7.06 7.1 -1.03 
Ccne1 5.01 5.47 -1.38 5.11 5.24 -1.09 
Psmg2 3.07 3.56 -1.40 3.13 3.24 -1.08 
E2f1 5.48 5.98 -1.41 4.57 4.76 -1.14 
Ppm1d 4.24 4.74 -1.41 3.76 4.13 -1.29 
Smc1a 3.99 4.48 -1.41 3.31 3.79 -1.40 
Npm2 9.46 9.98 -1.43 8.65 8.75 -1.07 
Cdc25a 4.36 4.88 -1.44 3.68 3.99 -1.25 
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Cks1b 3.01 3.56 -1.46 2.58 3.07 -1.41 
Cdkn1b 3.79 4.36 -1.48 2.5 3.11 -1.52 
Tfdp1 1.04 1.6 -1.48 1.08 1.42 -1.27 
Skp2 5.42 6 -1.49 6.31 6.77 -1.37 
Atm 5.56 6.14 -1.50 4.83 5.25 -1.34 
Mre11a 5.1 5.68 -1.50 5.87 5.95 -1.06 
Stag1 4.78 5.39 -1.52 3.86 4.37 -1.43 
Terf1 4.71 5.34 -1.54 4.7 5.29 -1.51 
Ccnb1 3.17 3.8 -1.55 3.11 4.38 -2.42 
Hus1 6.29 6.94 -1.57 6.08 6.76 -1.60 
Pcna 0.92 1.57 -1.57 1.33 2.25 -1.89 
Ccna2 3.55 4.25 -1.62 2.79 4.22 -2.69 
Ppp3ca 4.08 4.77 -1.62 2.86 3.16 -1.23 
Rad21 1.95 2.65 -1.62 1.4 2.05 -1.57 
Cdk4 1.2 1.91 -1.63 0.63 0.87 -1.18 
Inha 7.77 8.47 -1.63 6.97 7.05 -1.06 
Mtbp 5.13 5.84 -1.63 4.99 5.51 -1.43 
Mcm3 2.86 3.57 -1.64 3.13 3.98 -1.80 
Msh2 3.8 4.54 -1.66 3.71 4.12 -1.33 
Chek1 5.48 6.22 -1.67 5.8 6.76 -1.95 
Rad9 5.19 5.97 -1.72 4.73 5.23 -1.41 
Nek2 4.28 5.07 -1.73 4.87 6.22 -2.55 
Ccnb2 4.1 4.91 -1.74 4.1 5.13 -2.04 
Rad51 4.99 5.81 -1.77 5.45 6.73 -2.42 
Mad2l1 3.28 4.12 -1.79 3.27 4.4 -2.19 
Trp53 1.83 2.68 -1.81 1.85 2.64 -1.72 
Mcm4 2.32 3.18 -1.82 2.77 3.39 -1.54 
Rbl1 5.69 6.57 -1.85 5.21 6.09 -1.85 
Brca2 6.67 7.7 -2.04 5.97 6.64 -1.59 
Wee1 5.24 6.27 -2.04 5.58 5.94 -1.28 
Brca1 5.58 6.62 -2.06 5.7 7.24 -2.91 
Ccnf 3.71 4.76 -2.06 3.47 4.78 -2.49 
Mcm2 2.75 3.81 -2.07 3.15 4.42 -2.42 
Mki67 2.94 4.07 -2.19 1.75 3.49 -3.34 
E2f2 11.09 12.32 -2.35 11.35 11.75 -1.32 
Trp63 10.58 13.4 -7.09 11.7 11.79 -1.06 
Ppp2r3a 10.09 9.92 1.12 8.83 9.05 -1.17 
Camk2a 9.14 9.14 -1.00 8.09 6.95 2.2 
Pkd1 3.74 3.76 -1.01 2.73 2.43 1.23 
Apbb1 8.76 8.87 -1.08 6.27 6.22 1.04 
Ccnc 7.3 7.44 -1.10 5.99 5.82 1.13 
 at Thomas Jefferson Universi on July 31, 2012http://circres.ahajournals.org/Downloaded from 
 13 
 
Tsg101 7.03 7.17 -1.10 6.54 6.52 1.02 
Nfatc1 4.46 4.63 -1.12 2.93 2.91 1.01 
Sumo1 2.1 2.28 -1.13 1.76 1.61 1.11 
Gpr132 12.38 12.6 -1.17 11.95 11.79 1.12 
Abl1 9.49 9.76 -1.21 8.13 7.72 1.33 
Dst 3.12 3.44 -1.25 2.2 2.07 1.09 
Prm1 13.23 13.57 -1.26 12.07 11.79 1.21 
Gadd45a 5.06 5.42 -1.28 4.41 3.51 1.86 
Casp3 4.79 5.2 -1.32 3.98 3.86 1.09 
Ccna1 13.27 13.75 -1.39 12.07 11.79 1.21 
Slfn1 13.27 13.75 -1.39 12.07 11.79 1.21 
Camk2b 11.89 12.55 -1.58 10.26 9.78 1.40 
Myb 12.28 13.25 -1.96 11.85 11.79 1.04 
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Online Table IV: Cell cycle-focused RT-PCR gene arrays in CSP cells infected with sh-Scramble and sh-
IGFBP3 lentiviruses and treated with Vehicle or Wnt3a-CM (5 days).  
 
Cell cycle RT-PCR array 
Description Symbol 
Sh-Scramble Sh-IGFBP3 
(ΔCt) 
Fold 
change 
(ΔCt) 
Fold 
change 
Vehicle Wnt3a-CM Vehicle 
Wnt3a
-CM 
Minichromosome 
maintenance deficient 3 (S. 
cerevisiae) 
Mcm3 4.79 1.60 -9.18 1.58 2.00 1.33 
Cyclin B1 Ccnb1 6.55 3.65 -7.51 1.93 3.32 2.61 
Proliferating cell nuclear 
antigen Pcna 4.66 1.78 -7.40 1.52 1.97 1.36 
Cyclin-dependent kinase 2 Cdk2 7.43 4.56 -7.35 4.20 4.64 1.35 
Cyclin A2 Ccna2 5.21 2.69 -5.77 1.12 2.21 2.12 
Cyclin B2 Ccnb2 8.64 6.26 -5.23 4.61 5.02 1.33 
Breast cancer 1 Brca1 7.76 5.59 -4.53 4.59 5.71 2.17 
Minichromosome 
maintenance deficient 4 
homolog (S. cerevisiae) 
Mcm4 4.64 2.49 -4.46 2.06 2.25 1.14 
MAD2 mitotic arrest deficient-
like 1 (yeast) Mad2l1 5.72 3.60 -4.37 3.05 3.12 1.05 
E2F transcription factor 3 E2f3 7.48 5.55 -3.83 5.21 5.96 1.68 
Antigen identified by  
monoclonal antibody Ki 67 Mki67 3.21 1.36 -3.63 1.25 1.50 1.19 
Meiotic recombination 11  
homolog A (S. cerevisiae) Mre11a 8.64 6.82 -3.55 5.53 6.98 2.72 
Breast cancer 2 Brca2 7.38 5.58 -3.50 3.52 4.55 2.04 
Minichromosome 
maintenance  
deficient 2 mitotin (S. 
cerevisiae) 
Mcm2 4.85 3.17 -3.22 2.49 2.89 1.32 
RAN, member RAS 
oncogene family Ran 0.93 -0.63 -2.96 -1.10 -0.94 1.11 
Cyclin-dependent kinase 
inhibitor 1B Cdkn1b 5.02 3.48 -2.92 3.11 3.24 1.09 
Checkpoint kinase 1 homolog 
(S. pombe) Chek1 6.89 5.43 -2.77 5.45 5.60 1.11 
CDC28 protein kinase 1b Cks1b 4.51 3.05 -2.77 2.65 2.78 1.09 
Retinoblastoma-like 1 (p107) Rbl1 6.76 5.32 -2.73 5.50 5.60 1.07 
S-phase kinase-associated 
protein 2 (p45) Skp2 8.54 7.10 -2.73 6.01 7.48 2.76 
WEE 1 homolog 1 (S. pombe) Wee1 7.44 6.04 -2.65 5.08 6.36 2.42 
Caspase 3 Casp3 6.79 5.50 -2.46 4.30 5.99 3.22 
SMT3 suppressor of mif two 3  
homolog 1 (yeast) Sumo1 4.33 3.06 -2.43 3.35 3.37 1.01 
Cyclin F Ccnf 4.41 3.17 -2.38 2.59 2.63 1.03 
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Mdm2, transformed 3T3 cell 
double minute p53 binding 
protein 
Mtbp 5.70 4.50 -2.31 3.53 4.37 1.79 
Retinoblastoma-like 2 Rbl2 8.63 7.45 -2.28 6.41 7.28 1.82 
MutS homolog 2 (E. coli) Msh2 4.31 3.16 -2.23 2.30 2.65 1.27 
Pescadillo homolog 1, 
containing 
 BRCT domain (zebrafish) 
Pes1 1.99 0.86 -2.20 1.12 0.47 -1.57 
Telomeric repeat binding 
factor 1 Terf1 5.49 4.38 -2.17 4.98 5.02 1.03 
Ataxia telangiectasia mutated  
homolog (human) Atm 5.78 4.70 -2.13 3.43 4.60 2.24 
Tumor susceptibility gene 101 Tsg101 8.42 7.38 -2.07 5.42 6.43 2.01 
C-abl oncogene 1, receptor 
tyrosine kinase Abl1 7.41 6.60 -1.76 7.40 7.44 1.03 
RAD51 homolog (S. 
cerevisiae) Rad51 8.64 7.95 -1.62 7.17 7.68 1.42 
Protein phosphatase 1D 
magnesium-dependent, delta 
isoform 
Ppm1d 4.03 3.37 -1.59 2.86 2.93 1.05 
RAD21 homolog (S. pombe) Rad21 2.14 1.56 -1.50 1.58 1.21 -1.30 
Transformation related 
protein 53 Trp53 1.88 1.34 -1.46 1.27 0.98 -1.23 
Src homology 2 domain-
containing 
transforming protein C1 
Shc1 3.87 3.42 -1.37 2.41 2.92 1.42 
NIMA (never in mitosis gene 
a) related expressed kinase 2 Nek2 4.80 4.36 -1.36 3.33 3.34 1.00 
Cyclin C Ccnc 8.64 8.25 -1.32 7.27 7.13 -1.11 
Nucleophosmin/nucleoplasmi
n 2 Npm2 8.64 8.27 -1.30 8.47 8.03 -1.36 
Protein phosphatase 3, 
catalytic subunit, alpha 
isoform 
Ppp3ca 4.40 4.04 -1.29 2.79 2.66 -1.10 
Structural maintenance of  
chromosomes 1A Smc1a 4.22 3.91 -1.25 3.66 3.30 -1.29 
Transcription factor Dp 1 Tfdp1 2.08 1.77 -1.25 1.04 1.15 1.08 
Stromal antigen 1 Stag1 4.92 4.64 -1.22 4.49 4.20 -1.23 
Cyclin E1 Ccne1 4.33 4.07 -1.20 3.28 4.89 3.04 
E2F transcription factor 4 E2f4 2.94 2.70 -1.19 2.15 2.35 1.15 
E2F transcription factor 1 E2f1 5.18 4.95 -1.18 3.82 4.28 1.37 
RAD17 homolog (S. pombe) Rad17 4.83 4.60 -1.18 4.48 4.40 -1.06 
Adenylate kinase 1 Ak1 2.70 2.49 -1.16 1.27 2.16 1.85 
RAD9 homolog (S. pombe) Rad9 4.49 4.33 -1.12 4.37 3.99 -1.31 
Hus1 homolog (S. pombe) Hus1 5.87 5.73 -1.11 4.81 5.23 1.33 
Growth arrest and DNA  
damage-inducible 45 alpha 
Gadd45
a 4.31 4.19 -1.09 3.45 4.07 1.53 
Transformed mouse 3T3  
cell double minute 2 Mdm2 2.92 2.85 -1.06 1.47 1.94 1.38 
Proteasome (prosome, 
macropain) 
 assembly chaperone 2 
Psmg2 3.41 3.38 -1.03 2.73 3.04 1.24 
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Integrin beta 1 (fibronectin 
receptor beta) Itgb1 -4.12 -1.26 7.22 -2.38 -1.51 1.82 
Polycystic kidney disease 1 
homolog Pkd1 1.33 2.92 2.99 3.10 2.99 -1.08 
DNA-damage inducible 
transcript 3 Ddit3 1.64 3.22 2.97 3.24 2.55 -1.62 
Dystonin Dst 0.26 1.84 2.97 1.46 0.73 -1.66 
Sestrin 2 Sesn2 2.81 4.30 2.79 3.78 4.01 1.17 
Microtubule-actin crosslinking 
factor 1 Macf1 0.44 1.75 2.47 1.36 1.32 -1.03 
Cyclin D1 Ccnd1 1.46 2.70 2.35 1.66 2.58 1.89 
Cyclin-dependent kinase 
inhibitor 1A (P21) Cdkn1a -0.79 0.45 2.35 0.07 0.24 1.12 
Cyclin-dependent kinase 
inhibitor 2A Cdkn2a 0.62 1.81 2.27 1.02 1.57 1.46 
Calcium/calmodulin-
dependent protein kinase II 
alpha 
Camk2a 5.28 6.23 1.92 5.49 7.52 4.07 
CDK5 regulatory subunit 
associated protein 1 
Cdk5rap
1 5.73 6.49 1.68 5.84 6.16 1.24 
Stratifin Sfn 6.24 6.99 1.67 6.26 7.06 1.74 
Notch gene homolog 2 
(Drosophila) Notch2 3.58 4.27 1.60 3.73 3.74 1.00 
Nuclear factor of activated T-
cells, cytoplasmic, 
calcineurin-dependent 1 
Nfatc1 3.94 4.45 1.42 3.85 3.41 -1.36 
DnaJ (Hsp40) homolog, 
subfamily C, member 2 Dnajc2 2.04 2.44 1.31 1.89 1.77 -1.09 
Amyloid beta (A4) precursor 
protein-binding, family B, 
member 1 
Apbb1 5.56 5.93 1.29 5.68 5.79 1.08 
Cyclin-dependent kinase 4 Cdk4 0.74 1.03 1.22 0.86 0.80 -1.05 
Peripheral myelin protein 22 Pmp22 1.53 1.79 1.19 2.13 2.22 1.06 
Inhibin alpha Inha 6.58 6.81 1.17 7.22 6.23 -1.99 
TAF10 RNA polymerase II, 
TATA box  
binding protein (TBP)-
associated factor 
Taf10 0.11 0.22 1.07 0.10 -0.58 -1.61 
Cell division cycle 25 
homolog A (S. pombe) Cdc25a 3.27 3.37 1.07 3.31 3.45 1.10 
Calcium/calmodulin-
dependent protein kinase II, 
beta 
Camk2b N/A N/A N/A N/A N/A N/A 
Cyclin A1 Ccna1 N/A N/A N/A N/A N/A N/A 
E2F transcription factor 2 E2f2 N/A N/A N/A N/A N/A N/A 
G protein-coupled receptor 
132 Gpr132 N/A N/A N/A N/A N/A N/A 
Myeloblastosis oncogene Myb N/A N/A N/A N/A N/A N/A 
Protein phosphatase 2 
(formerly 2A), regulatory 
subunit B'', alpha 
Ppp2r3a N/A N/A N/A N/A N/A N/A 
Protamine 1 Prm1 N/A N/A N/A N/A N/A N/A 
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Schlafen 1 Slfn1 N/A N/A N/A N/A N/A N/A 
Transformation related 
protein 63 Trp63 N/A N/A N/A N/A N/A N/A 
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Online Table V:  Wnt signaling focused RT-PCR gene array in freshly isolated CSP cells 
from sham and 1 day post-MI mice.  
 
Wnt signaling RT-PCR array  
Description Symbol 
Day 1 post-MI (ΔCt) 
Sham post-MI 
Fold 
change 
Casein kinase 1, delta Csnk1d 2.59 3.22 -1.55* 
Jun oncogene Jun -2.42 -2.38 -1.02 
F-box and WD-40 domain protein 11 Fbxw11 5.69 5.72 -1.02 
Secreted frizzled-related protein 4 Sfrp4 5.67 5.72 -1.03 
Amino-terminal enhancer of split Aes 3.42 3.48 -1.04 
Cyclin D3 Ccnd3 2.18 2.24 -1.04 
Transducin-like enhancer of split 1, 
homolog of Drosophila E(spl) Tle1 4.56 4.69 -1.09 
Casein kinase 1, alpha 1 Csnk1a1 2.04 2.18 -1.10 
Frizzled homolog 1 (Drosophila) Fzd1 2.86 3.01 -1.10 
Low density lipoprotein receptor-related 
protein 6 Lrp6 2.76 2.92 -1.11 
Protein phosphatase 2a, 
regulatory subunit A (PR 65) Ppp2r1a 1.53 1.71 -1.12 
Casein kinase 2, alpha 1 polypeptide Csnk2a1 2.48 2.64 -1.12 
Protein phosphatase 2 (formerly 2A), 
catalytic subunit, alpha isoform Ppp2ca 1.39 1.58 -1.14 
Dishevelled 2, dsh homolog (Drosophila) Dvl2 4.31 4.52 -1.15 
Kringle containing transmembrane protein 
1 Kremen1 2.43 2.67 -1.17 
C-terminal binding protein 1 Ctbp1 1.62 1.90 -1.21 
Wingless-related MMTV integration site 4 Wnt4 5.44 5.72 -1.21 
Secreted frizzled-related protein 2 Sfrp2 2.07 2.37 -1.22 
Ras homolog gene family, member U Rhou 4.83 5.14 -1.24 
Secreted frizzled-related protein 1 Sfrp1 3.66 4.00 -1.26 
Fos-like antigen 1 Fosl1 2.72 3.08 -1.27 
Dishevelled, dsh homolog 1 (Drosophila) Dvl1 5.01 5.37 -1.28 
Catenin (cadherin associated protein), 
beta 1 Ctnnb1 0.37 0.78 -1.33 
SUMO/sentrin specific peptidase 2 Senp2 5.31 5.72 -1.33 
Low density lipoprotein receptor-related 
protein 5 Lrp5 2.51 2.97 -1.37 
Frizzled homolog 7 (Drosophila) Fzd7 3.80 4.26 -1.37 
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Frizzled homolog 2 (Drosophila) Fzd2 5.67 5.20 1.38 
Transcription factor 3 Tcf3 4.69 5.17 -1.39 
Frizzled homolog 4 (Drosophila) Fzd4 3.50 3.98 -1.39 
C-terminal binding protein 2 Ctbp2 1.93 2.41 -1.39 
Protein phosphatase 2d,  
regulatory subunit B (B56) Ppp2r5d 3.18 3.70 -1.43 
Axin 1 Axin1 3.51 4.13 -1.53 
Catenin beta interacting protein 1 Ctnnbip1 4.56 5.22 -1.57 
WNT1 inducible signaling pathway protein 
1 Wisp1 5.02 5.72 -1.63 
Frizzled homolog 5 (Drosophila) Fzd5 4.04 4.78 -1.67 
E1A binding protein p300 Ep300 4.61 5.37 -1.68 
Cyclin D1 Ccnd1 4.52 5.27 -1.68 
Frizzled homolog 6 (Drosophila) Fzd6 4.48 5.28 -1.73 
Naked cuticle 1 homolog (Drosophila) Nkd1 3.89 4.87 -1.98 
Adenomatosis polyposis coli Apc 4.03 5.24 -2.30 
Solute carrier family 9 (sodium/hydrogen 
exchanger), member 3 regulator 1 Slc9a3r1 5.53 5.53 1.00 
Myelocytomatosis oncogene Myc 2.90 2.89 1.00 
F-box and WD-40 domain protein 2 Fbxw2 3.22 3.20 1.01 
B-cell CLL/lymphoma 9 Bcl9 5.76 5.72 1.02 
Lymphoid enhancer binding factor 1 Lef1 5.76 5.72 1.02 
Frizzled homolog 8 (Drosophila) Fzd8 5.77 5.72 1.03 
Cyclin D2 Ccnd2 2.72 2.65 1.05 
SRY-box containing gene 17 Sox17 3.75 3.66 1.06 
Wingless-type MMTV integration site 9A Wnt9a 5.81 5.72 1.06 
Pygopus 1 Pygo1 5.69 5.59 1.07 
Wingless-related MMTV integration site 11 Wnt11 4.33 4.23 1.07 
Dishevelled associated activator of 
morphogenesis 1 Daam1 3.57 3.45 1.08 
Wingless related MMTV integration site 2b Wnt2b 5.15 5.00 1.10 
F-box and WD-40 domain protein 4 Fbxw4 5.87 5.72 1.10 
Frizzled homolog 3 (Drosophila) Fzd3 5.89 5.72 1.12 
DIX domain containing 1 Dixdc1 5.61 5.40 1.15 
Glycogen synthase kinase 3 beta Gsk3b 5.97 5.72 1.18 
Beta-transducin repeat containing protein Btrc 6.03 5.72 1.23 
Frizzled-related protein Frzb 2.15 1.81 1.26 
Porcupine homolog (Drosophila) Porcn 6.03 5.64 1.30 
Wingless-related MMTV integration site 5B Wnt5b 5.56 5.16 1.32 
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Wingless-related MMTV integration site 5A Wnt5a 6.15 5.72 1.34 
Transcription factor 7, T-cell specific Tcf7 5.86 5.21 1.57 
Follicle stimulating hormone beta Fshb 6.17 5.51 1.58 
Wingless-related MMTV integration site 16 Wnt16 6.17 5.44 1.65 
Wnt inhibitory factor 1 Wif1 4.42 3.08 2.52 
Dickkopf homolog 1 (Xenopus laevis) Dkk1 N/A N/A N/A 
Fibroblast growth factor 4 Fgf4 N/A N/A N/A 
Forkhead box N1 Foxn1 N/A N/A N/A 
Frequently rearranged in advanced T-cell 
lymphomas Frat1 N/A N/A N/A 
Nemo like kinase Nlk N/A N/A N/A 
Paired-like homeodomain transcription 
factor 2 Pitx2 N/A N/A N/A 
Brachyury T N/A N/A N/A 
Transducin-like enhancer of split 2, 
homolog of Drosophila E(spl) Tle2 N/A N/A N/A 
Wingless-related MMTV integration site 1 Wnt1 N/A N/A N/A 
Wingless related MMTV integration site 
10a Wnt10a N/A N/A N/A 
Wingless-related MMTV integration site 2 Wnt2 N/A N/A N/A 
Wingless-related MMTV integration site 3 Wnt3 N/A N/A N/A 
Wingless-related MMTV integration site 3A Wnt3a N/A N/A N/A 
Wingless-related MMTV integration site 6 Wnt6 N/A N/A N/A 
Wingless-related MMTV integration site 7A Wnt7a N/A N/A N/A 
Wingless-related MMTV integration site 7B Wnt7b N/A N/A N/A 
Wingless-related MMTV integration site 8A Wnt8a N/A N/A N/A 
Wingless related MMTV integration site 8b Wnt8b N/A N/A N/A 
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Online Table VI:  Wnt signaling focused RT-PCR gene array in freshly isolated CSP cells 
from sham and 3 days post-MI mice. 
 
Wnt signaling RT-PCR array  
Description Symbol 
Day 3 post-MI (ΔCt) 
Sham post-MI 
Fold 
change 
Frizzled homolog 5 (Drosophila) Fzd5 4.03 5.03 -1.99* 
Adenomatosis polyposis coli Apc 4.03 5.07 -2.07* 
Dishevelled 2, dsh homolog (Drosophila) Dvl2 4.30 5.47 -2.25* 
Amino-terminal enhancer of split Aes 3.42 4.75 -2.52* 
Transcription factor 3 Tcf3 4.68 6.09 -2.65* 
E1A binding protein p300 Ep300 4.61 6.02 -2.66* 
Secreted frizzled-related protein 4 Sfrp4 5.66 7.29 -3.00* 
Frizzled homolog 6 (Drosophila) Fzd6 4.48 6.44 -3.89* 
Ras homolog gene family, member U Rhou 4.83 4.84 -1.00 
Frizzled-related protein Frzb 2.15 2.18 -1.01 
Frizzled homolog 1 (Drosophila) Fzd1 2.86 2.91 -1.03 
Casein kinase 1, alpha 1 Csnk1a1 2.04 2.23 -1.13 
Wingless-related MMTV integration site 11 Wnt11 4.33 4.52 -1.14 
Transducin-like enhancer of split 1, 
homolog of Drosophila E(spl) Tle1 4.56 4.79 -1.16 
Myelocytomatosis oncogene Myc 2.90 3.16 -1.19 
Secreted frizzled-related protein 1 Sfrp1 3.66 3.96 -1.22 
Cyclin D1 Ccnd1 4.52 4.85 -1.25 
Protein phosphatase 2a, 
regulatory subunit A (PR 65) Ppp2r1a 1.53 1.91 -1.29 
F-box and WD-40 domain protein 2 Fbxw2 3.22 3.61 -1.30 
Wnt inhibitory factor 1 Wif1 4.42 4.85 -1.34 
SUMO/sentrin specific peptidase 2 Senp2 5.31 5.74 -1.34 
Fos-like antigen 1 Fosl1 2.72 3.19 -1.38 
C-terminal binding protein 1 Ctbp1 1.62 2.10 -1.39 
Low density lipoprotein receptor-related 
protein 6 Lrp6 2.76 3.26 -1.40 
Dishevelled associated activator of 
morphogenesis 1 Daam1 3.57 4.12 -1.45 
Transcription factor 7, T-cell specific Tcf7 5.86 6.42 -1.47 
F-box and WD-40 domain protein 11 Fbxw11 5.69 6.32 -1.54 
Axin 1 Axin1 3.51 4.15 -1.55 
Catenin (cadherin associated protein), 
beta 1 Ctnnb1 0.37 1.03 -1.57 
Kringle containing transmembrane protein 
1 Kremen1 2.43 3.13 -1.61 
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Frizzled homolog 2 (Drosophila) Fzd2 5.67 6.36 -1.61 
Casein kinase 1, delta Csnk1d 2.59 3.31 -1.63 
Solute carrier family 9 (sodium/hydrogen 
exchanger), member 3 regulator 1 Slc9a3r1 5.53 6.25 -1.64 
C-terminal binding protein 2 Ctbp2 1.93 2.72 -1.72 
Glycogen synthase kinase 3 beta Gsk3b 5.97 6.76 -1.73 
Wingless related MMTV integration site 2b Wnt2b 5.15 5.94 -1.73 
Cyclin D3 Ccnd3 2.18 2.99 -1.74 
Wingless-related MMTV integration site 4 Wnt4 5.44 6.25 -1.75 
Dishevelled, dsh homolog 1 (Drosophila) Dvl1 5.01 5.82 -1.75 
Casein kinase 2, alpha 1 polypeptide Csnk2a1 2.48 3.30 -1.76 
Low density lipoprotein receptor-related 
protein 5 Lrp5 2.51 3.34 -1.77 
Wingless-related MMTV integration site 5A Wnt5a 6.15 7.00 -1.80 
Cyclin D2 Ccnd2 2.72 3.59 -1.82 
Frizzled homolog 3 (Drosophila) Fzd3 5.89 6.83 -1.91 
Jun oncogene Jun -2.42 -1.47 -1.92 
Porcupine homolog (Drosophila) Porcn 6.03 7.00 -1.96 
Frizzled homolog 8 (Drosophila) Fzd8 5.77 6.76 -1.97 
Frizzled homolog 7 (Drosophila) Fzd7 3.80 4.85 -2.06 
F-box and WD-40 domain protein 4 Fbxw4 5.87 6.95 -2.11 
Wingless-type MMTV integration site 9A Wnt9a 5.81 6.90 -2.11 
Catenin beta interacting protein 1 Ctnnbip1 4.56 5.70 -2.20 
Wingless-related MMTV integration site 5B Wnt5b 5.56 6.71 -2.21 
B-cell CLL/lymphoma 9 Bcl9 5.76 6.94 -2.25 
Frizzled homolog 4 (Drosophila) Fzd4 3.50 4.69 -2.27 
Naked cuticle 1 homolog (Drosophila) Nkd1 3.89 5.07 -2.27 
DIX domain containing 1 Dixdc1 5.61 6.81 -2.28 
Beta-transducin repeat containing protein Btrc 6.03 7.23 -2.29 
Lymphoid enhancer binding factor 1 Lef1 5.76 7.15 -2.61 
Pygopus 1 Pygo1 5.69 7.16 -2.76 
SRY-box containing gene 17 Sox17 3.75 5.44 -3.23 
Secreted frizzled-related protein 2 Sfrp2 2.07 1.57 1.41 
WNT1 inducible signaling pathway protein 
1 Wisp1 5.02 4.71 1.23 
Protein phosphatase 2d,  
regulatory subunit B (B56) Ppp2r5d 3.18 3.03 1.11 
Protein phosphatase 2 (formerly 2A), 
catalytic subunit, alpha isoform Ppp2ca 1.39 1.27 1.08 
Dickkopf homolog 1 (Xenopus laevis) Dkk1 N/A N/A N/A 
Fibroblast growth factor 4 Fgf4 N/A N/A N/A 
Forkhead box N1 Foxn1 N/A N/A N/A 
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Frequently rearranged in advanced T-cell 
lymphomas Frat1 N/A N/A N/A 
Follicle stimulating hormone beta Fshb N/A N/A N/A 
Nemo like kinase Nlk N/A N/A N/A 
Paired-like homeodomain transcription 
factor 2 Pitx2 N/A N/A N/A 
Brachyury T N/A N/A N/A 
Transducin-like enhancer of split 2, 
homolog of Drosophila E(spl) Tle2 N/A N/A N/A 
Wingless-related MMTV integration site 1 Wnt1 N/A N/A N/A 
Wingless related MMTV integration site 
10a Wnt10a N/A N/A N/A 
Wingless-related MMTV integration site 16 Wnt16 N/A N/A N/A 
Wingless-related MMTV integration site 2 Wnt2 N/A N/A N/A 
Wingless-related MMTV integration site 3 Wnt3 N/A N/A N/A 
Wingless-related MMTV integration site 3A Wnt3a N/A N/A N/A 
Wingless-related MMTV integration site 6 Wnt6 N/A N/A N/A 
Wingless-related MMTV integration site 7A Wnt7a N/A N/A N/A 
Wingless-related MMTV integration site 7B Wnt7b N/A N/A N/A 
Wingless-related MMTV integration site 8A Wnt8a N/A N/A N/A 
Wingless related MMTV integration site 8b Wnt8b N/A N/A N/A 
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Online Table VII:  Wnt signaling focused RT-PCR gene array in freshly isolated CSP cells 
from sham and 7 days post-MI mice. 
 
Wnt signaling RT-PCR array 
Description Symbol 
Day 7 post-MI (ΔCt) 
Sham post-MI Fold change 
Catenin (cadherin associated protein), beta 1 Ctnnb1 0.09 0.47 -1.30* 
C-terminal binding protein 1 Ctbp1 1.73 2.36 -1.54* 
Wnt inhibitory factor 1 Wif1 3.50 4.34 -1.78* 
Casein kinase 1, alpha 1 Csnk1a1 1.99 2.87 -1.83* 
Cyclin D2 Ccnd2 2.13 3.58 -2.74* 
Amino-terminal enhancer of split Aes 2.77 4.74 -3.91* 
Protein phosphatase 2a, 
regulatory subunit A (PR 65) Ppp2r1a 1.79 1.80 -1.00 
Frizzled homolog 1 (Drosophila) Fzd1 3.11 3.13 -1.01 
Pygopus 1 Pygo1 5.13 5.17 -1.02 
Transcription factor 3 Tcf3 4.80 4.84 -1.02 
Casein kinase 2, alpha 1 polypeptide Csnk2a1 2.83 2.88 -1.03 
Solute carrier family 9 (sodium/hydrogen 
exchanger), member 3 regulator 1 Slc9a3r1 4.94 5.02 -1.05 
Frizzled-related protein Frzb 2.12 2.23 -1.07 
Frizzled homolog 5 (Drosophila) Fzd5 4.11 4.22 -1.07 
Wingless-related MMTV integration site 11 Wnt11 4.53 4.66 -1.09 
Dishevelled 2, dsh homolog (Drosophila) Dvl2 4.16 4.31 -1.10 
Frizzled homolog 3 (Drosophila) Fzd3 5.09 5.34 -1.18 
Myelocytomatosis oncogene Myc 3.08 3.32 -1.18 
Frizzled homolog 8 (Drosophila) Fzd8 5.01 5.27 -1.19 
Frizzled homolog 4 (Drosophila) Fzd4 3.14 3.41 -1.2 
Secreted frizzled-related protein 1 Sfrp1 3.78 4.06 -1.21 
Secreted frizzled-related protein 4 Sfrp4 5.04 5.34 -1.22 
Protein phosphatase 2d,  
regulatory subunit B (B56) Ppp2r5d 3.04 3.37 -1.24 
C-terminal binding protein 2 Ctbp2 1.86 2.25 -1.31 
Casein kinase 1, delta Csnk1d 2.82 3.26 -1.35 
Low density lipoprotein receptor-related 
protein 6 Lrp6 2.57 3.01 -1.35 
B-cell CLL/lymphoma 9 Bcl9 4.88 5.34 -1.36 
Naked cuticle 1 homolog (Drosophila) Nkd1 3.72 4.16 -1.36 
F-box and WD-40 domain protein 2 Fbxw2 2.66 3.12 -1.37 
E1A binding protein p300 Ep300 4.21 4.69 -1.38 
SRY-box containing gene 17 Sox17 2.71 3.19 -1.39 
Transcription factor 7, T-cell specific Tcf7 4.37 4.85 -1.39 
Kringle containing transmembrane protein 1 Kremen1 2.47 2.96 -1.40 
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Low density lipoprotein receptor-related 
protein 5 Lrp5 2.10 2.63 -1.44 
Porcupine homolog (Drosophila) Porcn 4.79 5.34 -1.45 
Frizzled homolog 7 (Drosophila) Fzd7 3.93 4.49 -1.47 
Wingless-related MMTV integration site 5A Wnt5a 4.72 5.29 -1.48 
Jun oncogene Jun -2.87 -2.22 -1.57 
SUMO/sentrin specific peptidase 2 Senp2 4.24 4.93 -1.6 
Ras homolog gene family, member U Rhou 4.11 4.80 -1.61 
Frizzled homolog 2 (Drosophila) Fzd2 4.63 5.34 -1.62 
Catenin beta interacting protein 1 Ctnnbip1 3.96 4.74 -1.71 
Cyclin D3 Ccnd3 1.33 2.12 -1.72 
Wingless related MMTV integration site 2b Wnt2b 4.05 4.85 -1.73 
Adenomatosis polyposis coli Apc 3.79 4.64 -1.80 
Fos-like antigen 1 Fosl1 3.24 4.17 -1.90 
Cyclin D1 Ccnd1 3.46 4.41 -1.92 
Axin 1 Axin1 3.45 4.47 -2.01 
Dishevelled associated activator of 
morphogenesis 1 Daam1 3.15 4.20 -2.06 
Dishevelled, dsh homolog 1 (Drosophila) Dvl1 3.91 5.06 -2.21 
Secreted frizzled-related protein 2 Sfrp2 3.07 1.66 2.66* 
Transducin-like enhancer of split 1, homolog of 
Drosophila E(spl) Tle1 5.04 4.21 1.77 
Wingless-related MMTV integration site 5B Wnt5b 4.70 4.44 1.19 
Protein phosphatase 2 (formerly 2A), catalytic 
subunit, alpha isoform Ppp2ca 1.42 1.28 1.09 
WNT1 inducible signaling pathway protein 1 Wisp1 5.13 5.01 1.09 
Wingless-related MMTV integration site 4 Wnt4 5.13 5.00 1.09 
Frizzled homolog 6 (Drosophila) Fzd6 3.97 3.96 1.00 
Glycogen synthase kinase 3 beta Gsk3b 5.13 5.12 1.00 
Beta-transducin repeat containing protein Btrc N/A N/A N/A 
DIX domain containing 1 Dixdc1 N/A N/A N/A 
Dickkopf homolog 1 (Xenopus laevis) Dkk1 N/A N/A N/A 
F-box and WD-40 domain protein 11 Fbxw11 N/A N/A N/A 
F-box and WD-40 domain protein 4 Fbxw4 N/A N/A N/A 
Fibroblast growth factor 4 Fgf4 N/A N/A N/A 
Forkhead box N1 Foxn1 N/A N/A N/A 
Frequently rearranged in advanced T-cell 
lymphomas Frat1 N/A N/A N/A 
Follicle stimulating hormone beta Fshb N/A N/A N/A 
Lymphoid enhancer binding factor 1 Lef1 N/A N/A N/A 
Nemo like kinase Nlk N/A N/A N/A 
Paired-like homeodomain transcription factor 2 Pitx2 N/A N/A N/A 
Brachyury T N/A N/A N/A 
 at Thomas Jefferson Universi on July 31, 2012http://circres.ahajournals.org/Downloaded from 
 26 
 
Transducin-like enhancer of split 2, homolog of 
Drosophila E(spl) Tle2 N/A N/A N/A 
Wingless-related MMTV integration site 1 Wnt1 N/A N/A N/A 
Wingless related MMTV integration site 10a Wnt10a N/A N/A N/A 
Wingless-related MMTV integration site 16 Wnt16 N/A N/A N/A 
Wingless-related MMTV integration site 2 Wnt2 N/A N/A N/A 
Wingless-related MMTV integration site 3 Wnt3 N/A N/A N/A 
Wingless-related MMTV integration site 3A Wnt3a N/A N/A N/A 
Wingless-related MMTV integration site 6 Wnt6 N/A N/A N/A 
Wingless-related MMTV integration site 7A Wnt7a N/A N/A N/A 
Wingless-related MMTV integration site 7B Wnt7b N/A N/A N/A 
Wingless-related MMTV integration site 8A Wnt8a N/A N/A N/A 
Wingless related MMTV integration site 8b Wnt8b N/A N/A N/A 
Wingless-type MMTV integration site 9A Wnt9a N/A N/A N/A 
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Online Table VIII:  Order of Wnt signaling relates genes on the RT-PCR array 96-well plate corresponding to 
Figure 4A-C.  MGDC (Mouse Genomic DNA Contamination), RTC (Reverse Transcription Control) and PPC 
(Polymerase PCR Control) represent internal array controls and are not depicted in Figure 4A-C.   
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A Aes Apc Axin1 Bcl9 Btrc Ctnnbi
p1 
Ccn
d1 
Ccnd
2 
Ccnd3 Csnk1
a1 
Csnk1
d 
Csnk2
a1 
B Ctbp
1 
Ctbp2 Ctnnb1 Daam
1 
Dixdc1 Dkk1 Dvl1 Dvl2 Ep300 Fbxw1
1 
Fbxw2 Fbxw4 
C Fgf4 Fosl1 Foxn1 Frat1 Frzb Fshb Fzd1 Fzd2 Fzd3 Fzd4 Fzd5 Fzd6 
D Fzd7 Fzd8 Gsk3b Jun Kreme
n1 
Lef1 Lrp5 Lrp6 Myc Nkd1 Nlk Pitx2 
E Porc
n 
Ppp2
ca 
Ppp2r1
a 
Ppp2r
5d 
Pygo1 Rhou Sen
p2 
Sfrp1 Sfrp2 Sfrp4 Slc9a3
r1 
Sox17 
F T Tcf7l
1 
Tcf7 Tle1 Tle2 Wif1 Wisp
1 
Wnt1 Wnt10
a 
Wnt11 Wnt16 Wnt2 
G Wnt
2b 
Wnt3 Wnt3a Wnt4 Wnt5a Wnt5b Wnt
6 
Wnt7
a 
Wnt7b Wnt8a Wnt8b Wnt9a 
H Gus
b 
Hprt Hsp90a
b1 
Gapdh Actb MGDC RTC RTC RTC PPC PPC PPC 
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Online Figure I 
Online Figure I:  Administration of SFRP2 does not alter CSP cell proliferation 
capacity in vitro.  Treatment of CSP cells with increasing concentrations of SFRP2 
protein had no effect on CSP cell numbers compared to Vehicle treated cells (n=3).  
Data are mean ± s.e.m.  Cell number in fold change is normalized to Vehicle group.  
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IGFBP3 
Online Figure II:  Activation of Wnt signaling pathway up-regulates IGFBP3 
expression in CSP cells.  (A) Scatter plot analysis of pathway finder RT-PCR gene array 
in CSP cells following treatment (6 days) with Vehicle or Wnt3a-CM.  IGFBP3 (red dot) was 
profoundly up-regulated among various genes related to different signaling pathways (n=3).  
The gene corresponding to each number can be found in Online Table II (second column). 
(B) Quantification of Western blot analysis of IGFBP3 protein expression in CSP cells 
following treatment with Wnt3a-CM (48 hours) (n=3).  Data are mean ± s.e.m.  * P≤0.05.  
 * 
Online Figure II 
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* 
Online Figure III:  Lentivirus-mediated over-expression of IGFBP3.  RT-PCR mRNA 
expression analysis of IGFBP3 in CSP cells infected with Mock or IGFBP3-over-expressing 
lentivirus (IGFBP3 o/e) (n=3).  Data are mean ± s.e.m.  * P≤0.05.  
Online Figure III 
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Online Figure IV:  shRNA mediated down-regulation of IGFBP3.  Quantification of 
Western blot analysis of IGFBP3 protein expression in sh-Scramble and sh-IGFBP3 CSP 
cells (n=3).  Data are mean ± s.e.m.  * P ≤ 0.05. 
* 
Online Figure IV 
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 * 
A 
B 
C 
Online Figure V:  IGF-1 increases CSP proliferation capacity.  (A) Treatment of CSP 
cells with 200ng/ml of IGF-1 protein resulted in increased proliferation capacity compared to 
Vehicle treated cells (n=3).  RT-PCR mRNA expression analysis of (B) IGF-1R1 and (C) 
IGF-1R2  following Vehicle and Wnt3a treatment (n=3).  Data are mean ± s.e.m.  * P ≤ 0.05. 
Online Figure V 
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DAPI (Nuclei) Alexa-555 (α-s-Actin) Alexa488 (BrdU) 
Online Figure VI:  BrdU+ cardiomyocytes in infarct/border zone  area of r-Wnt3a-injected 
heart.  (A-D) Each panel shows a series of 12 representative confocal z-stack immuno-fluorescent 
images of BrdU+ cardiomyocytes in high magnification (x200).  White arrowheads indicate the 
position of four BrdU+ cardiomyocytes.  Myocardial sections were immuno-labeled with (A) DAPI 
(blue), (B) α-sarcomeric-actin (red), (C) BrdU (green).  (D) Merged picture.  (Scale bars, 5 μm).  
Online Figure VI 
A B 
C D 
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* 
A B 
Online Figure VII 
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Online Figure VII:  Administration of r-Wnt3a increases cardiomyocyte cell death 
post-MI.  Injection of r-Wnt3a resulted in (A) increased Tunel+ cardiomyocytes in the 
infarct/border zone area one week post-MI compared to Vehicle injected hearts.  (B) r-
Wnt3a had no effect on total cell death (Vehicle n=4, r-Wnt3a n=5).   
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Sham Vehicle 
r-Wnt3a 
A 
C 
B 
D 
Online Figure VIII:  Administration of r-Wnt3a does not alter cardiomyocyte cross-
sectional area post-MI.  Representative examples of WGA staining in (A) Sham, (B) 
Vehicle and (C) r-Wnt3a injected hearts one week post-MI.  (D) Quantification of 
cardiomyocyte cross-sectional area revealed no significant differences between the 
groups (n=4).  Sections were immuno-labeled with WGA (red) and DAPI (blue). A.U. 
arbitrary units. (Scale bars 20 μm).  
Online Figure VIII 
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